DOTA COMPOUNDS AND USES THEREOF

RELATED APPLICATIONS

[0001] The present application claims priority under 35 U.S.C. § 119(e) to U.S. provisional application USSN 62/684,573, filed June 13, 2018, which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

[0002] Catalyzed reporter deposition (CARD) is a method of signal amplification useful in assaying biological samples for analyte detection. See U.S. Patent Nos. 5,731 ,158, 5,583,001, and 5,196,306 wiiich are hereby incorporated by reference. The CARD method utilizes an analyte-dependent enzyme activation system (ADEAS) to catalyze the deposition of reporter groups (e.g., fluorescein, biotin) onto a receptor, the receptor being part of or added to a surface in contact with the components of the assay. These enzymatically deposited labels are detected directly or indirectly, resulting in signal amplification and improved detection limits. Peroxidases, such as horseradish peroxidase (HRP) are the preferred enzymes for the method.

[0003] In the method, the peroxidase oxidizes a hydrogen-donating moiety of a substrate conjugate comprising a labeled compound. When the enzyme and the substrate react, a reactive intermediate is formed, which binds covalently with electron-rich residues near the receptor of the reactive intermediate. Hydrogen-donating moieties that are reactive with peroxidase enzymes include substituted phenols, such as tyramides, tyramines, and p- hydroxycinnamoyl-containing compounds. Specific reporters attached to the conjugate can be detected by fluorescence or light microscopy at the specific site of covalent attachment.

[0004] An ongoing need exists to identify molecules useful in the CARD method that can effectively bind specific target analytes to improve analyte detection.

SUMMARY OF THE INVENTION

[0005] The macrocycle 1 ,4,7, 10-tetraazacyclododecane-l ,4,7-tetraacetic acid (DOTA) is a chelating agent that can be employed in constructing compounds useful in the CARD method of detecting analytes in biological samples. In particular, the chelated form of DOTA can serve as a reporter moiety and be linked to reactive molecules (e.g., phenols) to form a compound that can bind to specific biological target molecules for analyte detection. The present disclosure describes DOTA-tyramide, DOTA-tyramine, and DOTA-cinnamamide compounds, salts, and chelate complexes thereof that are useful for site-specific binding and analyte detection. The DOTA containing compounds offer advantages over existing reporter compounds because the DOTA moiety can be detected directly (e.g., by mass spectrometry based imaging microscopy).

[0006] In one aspect, provided are compounds of Formula (I):

G)

and salts thereof wherein:

G is a chelating moiety;

R ¹ is substituted or unsubstituted alkylene, a bond, -0-, -S-, or -NR ^A -;

R ² is a bond, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;

X ¹ is a bond or N;

X is O or S;

R ³ is hydrogen, substituted or unsubstituted Ci-Ce alkyl, or a nitrogen protecting group;

R ⁴ is substituted or unsubstituted C ₂ -C. ₆ heteroaliphatic, substituted or unsubstituted C ₂ -C ₆ alkylene, substituted or unsubstituted C ₂ -C ₆ alkenylene, or substituted or unsubstituted C ₂ -C ₆ alkynylene;

R ⁵ is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aikynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A ) ₂ , or -OR ⁴ :

R ⁶ is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aikynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A ) ₂ , or -OR ^A ;

R ⁷ is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aikynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A ) ₂ , or -OR ⁴ ; R ^s is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aikynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A ) ₂ , or -OR ^A ; and each occurrence of R ^A is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aikynyl, substituted or unsubstituted heteroalkyl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom, or two R ^A gr oups are joined to form a substituted or unsubstituted heterocyclic ring.

[0007] In certain embodiments, the compound of Formula (I) is a compound of Formula (I- a):

(I-a)

and salts thereof, wherein:

R ¹ is substituted or imsubstituted alkylene, a bond, -0-, -S-, or -NR ^A -;

R ² is substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;

X is O or S;

R ³ is hydrogen, substituted or unsubstituted Ci-Ce alkyl, or a nitrogen protecting group;

R ⁴ is substituted or unsubstituted C ₂ -C. ₆ heteroaliphatic, substituted or unsubstituted C ₂ -C ₆ alkylene, substituted or unsubstituted C ₂ -C ₆ alkenylene, or substituted or unsubstituted C2-C6 alkynylene;

R ⁵ is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aikynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A )?, or -OR ⁴ ;

R ⁶ is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aikynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A ) ₂ , or -OR ⁴ ;

R' is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A )2, or -OR ⁴ ;

R ⁸ is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl. substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A ) ₂ , or -OR ^A ; and

each occurrence of R ^A is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom, or tw o R ^A groups are joined to form a substituted or unsubstituted heterocyclic ring.

[0008] Exemplary' compounds of Formula (I) include, but are not limited to:

and salts thereof. [0009] In another aspect, provided are salts comprising a compound of Formula (I). In certain embodiments, the salt comprises a metal counterion (e.g., bismuth, lead, yttrium, cadmium, mercury, actinium, thorium, strontium, or a lanthanide). In certain embodiments, the metal counterion is yttrium, praseodymium, or lutetium.

[0010] In another aspect, provided are chelate complexes comprising a compound of Formula (I), or a salt of a compound of Formula (I). In certain embodiments, the chelate complex is a trivalent complex.

[0011] Exemplary' chelate complexes comprising compounds of Formula (I) include, but are not limited to:

[0012] In another aspect, provided are methods of detecting an analyte, the method comprising reacting an enzyme (e.g., a peroxidase) with a chelate complex comprising a compound of Formula (I), or a salt thereof, to form an oxidized chelate complex; contacting the oxidized chelate complex with an biological sample; and detecting the analyte in the biological sample. In certain embodiments, the method further comprises covalent binding of the oxidized chelate complex with the analyte. [0013] In another aspect, provided are kits comprising a compound of Formula (I) or a salt thereof, or a chelate complex comprising a compound of Formula (I). In certain embodiments, the kit further comprises distractions for use.

[0014] The details of certain embodiments of the invention are set forth in the Detailed Description of Certain Embodiments, as described below. Other features, objects, and advantages of the invention will be apparent from the Definitions, Examples, and Claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 is a series of micrographs showing results of CARD assays employing exemplary compounds of the disclosure. The expression of the intermediate filament protein nestin was detected in normal human kidney podocytes using a goat anti-nestin polyclonal antibody with a rabbit anti-goat secondary horseradish peroxidase/ 3,3'-diaminobenzidine (DAB) chromogenic assay and standard light microscopy (Figure I A). The chromogenic signal for nestin expression was not seen with negative control conditions including without anti-nestin primary antibody (Figure 1C) or without secondary antibody (Figure IB). When DAB was replaced with exemplary compounds 1, 2, and 3 complexed to PC (Figure IE, Figure II, Figure 1M) or Y ³⁺ (Figure IF, Figure 1J, Figure IN), the complex was oxidized by peroxidase and deposited at the site of the anti-nestin antibody. This specific deposition of complex was detected with an anti-DOTA chelate antibody (clone 2D12.5) chromogenic assay using DAB (Figure IE, Figure II, Figure 1M, Figure IF, Figure 1J, Figure IN). Empty DOTA was not recognized by the anti-DOTA chelate antibody (clone 2D12.5), therefore chromogenic signal was not seen in these assay conditions (Figure 1G, Figure IK, Figure lO). Nestin-specific signal was not seen without anti-DOTA chelate antibody (Figure 1H, Figure 1L, Figure IP) or without the DOTA chelate complex in the anti-DOTA antibody assay (Figure ID).

[0016] Figure 2 is a series of images showing detection of compounds 1 and 3 using a mass spectrometry imaging device. The expression of the cytokeratin 7 (CK7) intermediate filament protein was detected in normal human placenta sections (4mhi; formalin fixation and paraffin embedded) with immunohistochemistry using a mouse anti-CK7 primary antibody followed by an anti-mouse secondary horseradish peroxidase/ 3,3’-diaminobenzidine (DAB) chromogenic assay and a standard light microscope (Ff). When DAB was replaced with compound 1 or 3 chelating Pr’ (Figure 2A, Figure 2B) or Y ³ (Figure 2C, Figure 2D), the complex was oxidized by peroxidase and deposited at the site of the anti-CK7 primary antibody. The deposited complexes were detected. Secondary ion mass spectrometry imaging peaks of ^' Pr’ (molecular weight = 141 g/mol) and Y ³⁺ (molecular weight 88.9 = g/mol) containing compounds are shown with adjacent final images from the device (Figures 2A-D showing signal in white) comparable to the specific staining of the placental syncytiotrophoblast cells shown with standard DAB staining (Figure 2H) and highlighted on a hematoxylin and eosin stained section (Figure 21). The arrow in Figure 21 refers to the syncytiotrophoblast layer of placenta. As a control, compounds 1 and 3 not chelated to a metal were not recognized by the mass spectrometry imaging device and therefore specific CK7 signal was not seen using these control assay conditions (Figure 2E, Figure 2F). The dilution of the compound is shown parenthetically.

DEFINITIONS

Chemical definitions

[0017] Definitions of specific functional groups and chemical temis are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 ^th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March, March’s Advanced Organic Chemistry, 5 ^th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modem Methods of Organic Synthesis, 3 ^rd Edition, Cambridge University Press, Cambridge, 1987.

[0018] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g. , enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al, Enantiomers, Racemates and Resolutions (Wiley Interscience, New _' York, 1981); Wilen et al, Tetrahedron 33:2725 (1977); Eliel, E.L., Stereochemistry’ of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S.H., Tables of Resolving Agents and Optical Resolutions, p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The invention additionally encompasses compounds as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.

[0019] In a formula, ~ ^w is a single bond where the stereochemistry of the moieties immediately attached thereto is not specified,— is absent or a single bond, and =-=-= or =-=-= is a single or double bond.

[0020] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, replacement of ¹⁹ F with ^iS F, or the replacement of ¹² C with ⁱ³ C or ¹⁴ C are within the scope of the disclosure. Such compounds are useful, for example, as analytical tools or probes in biological assays.

[0021] When a range of values is listed, it is intended to encompass each value and sub- range within the range. For example“Ci-6 alkyl” is intended to encompass, Ci, C ₂ , C ₃ , C ₄ , Cs, C _6, Ci-6, Ci-5, Ci-4, Ci-3, Ci-2, C ₂ -6, C ₂ -s, C _2-4 , C _2-3 , C _3-6 , C _3-5, C _H C ₄ -6, C _4-5 , and Cs-6 alkyl.

[0022] The term“aliphatic” refers to alkyl, alkenyl, alkynyl, and carbocyclic groups.

Likewise, the term“heteroaliphatic” refers to heteroalkyl, heteroalkenyl, heteroalkynyl, and heterocyclic groups.

[0023] The term“alkyl” refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 10 carbon atoms (“Ci-io alkyl”) hr some embodiments, an alkyl group has 1 to 9 carbon atoms (“Ci-g alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“Ci-s alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“Ci _-7 alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“Ci- ₆ alkyl”) hr some embodiments, an alkyl group has 1 to 5 carbon atoms (' C alkyl”).

In some embodiments, an alkyl group has 1 to 4 carbon atoms (“Ci _-4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“Ci _-3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“Ci _-2 alkyl”) hr some embodiments, an alkyl group has 1 carbon atom (“Ci alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C _2-6 alkyl”). Examples of Ci- ₆ alkyl groups include methyl (Ci), ethyl (C ₂ ), propyl (C ₃ ) (e.g., n-propyl, isopropyl), butyl (C ₄ ) (e.g., n-butyl, tert-butyl, sec -butyl, iso-butyl), pentyl (Cs) (e.g., n-pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2-butanyl, tertiary amyl), and hexyl (CVi) (e.g., n-hexyl). Additional examples of alkyl groups include n-heptyl (C ₇ ), n- octyl (Cs), and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an“unsubstituted alkyl”) or substituted (a“substituted alkyl”) with one or more substituents (e.g., halogen, such as F). In certain embodiments, the alkyl group is an unsubstituted C MO alkyl (such as unsubstituted Ci-e alkyl, e.g., -CH (Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, e.g. , unsubstituted n-propyl (n-Pr), unsubstituted isopropyl (i-Pr)), unsubstituted butyl (Bu, e.g., unsubstituted n-buty (n-Bu), unsubstituted tert-butyl (tert-Bu or t-Bu), unsubstituted sec-butyl (sec-Bu), unsubstituted isobutyl (i-Bu)). In certain embodiments, the alkyl group is a substituted Ci-io alkyl (such as substituted Ci-b alkyl, e.g., -CF3, Bn).

[0024] The tenn“haloalkyl” is a substituted alkyl group, wherein one or more of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo. In some embodiments, the haloalkyl moiety has 1 to 8 carbon atoms (“Ci-s haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 6 carbon atoms (“Ci- ₆ haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 4 carbon atoms (“C 1-4 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 3 carbon atoms (“Ci _-3 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 2 carbon atoms (“C _1-2 haloalkyl”). Examples of haloalkyl groups include -CHF ₂ , -CH ₂ F, -CF ₃ , -CH2CF3, -CF2CF3, -CF2CF2CF3, -CCh, -CFCb, -CF ₂ CI, and the like.

[0025] The term“heteroalkyl” refers to an alkyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (/.£?., inserted between adjacent carbon atoms oi) and/or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 20 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroCi-20 alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 18 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroCi-18 alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 16 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroCi-i ₆ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 14 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroCi-14 alkyl”). In some

embodiments, a heteroalkyl group is a saturated group having 1 to 12 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroCi-12 alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 10 carbon atoms and 1 or more

heteroatoms within the parent chain (“heteroCi-io alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroCi-s alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 6 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroCi-6 alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroCi-4 alkyl”). In some embodiments, a heteroaikyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom within the parent chain (“heteroCi- ₃ alkyl”). In some embodiments, a heteroaikyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom within the parent chain (“heteroCi-2 alkyl”). In some embodiments, a heteroaikyl group is a saturated group having 1 carbon atom and 1 heteroatom (“heteroCi alkyl”). In some embodiments, the heteroaikyl group defined herein is a partially unsaturated group having 1 or more heteroatoms within the parent chain and at least one unsaturated carbon, such as a carbonyl group. For example, a heteroaikyl group may comprise an amide or ester functionality in its parent chain such that one or more carbon atoms are unsaturated carbonyl groups. Unless otherwise specified , each instance of a heteroaikyl group is independently unsubstituted (an “unsubstituted heteroaikyl”) or substituted (a“substituted heteroaikyl”) with one or more substituents. In certain embodiments, the heteroaikyl group is an unsubstituted heteroCi-20 alkyl. In certain embodiments, the heteroaikyl group is an unsubstituted heteroCi-io alkyl. In certain embodiments, the heteroaikyl group is a substituted heteroCi-20 alkyl. In certain embodiments, the heteroaikyl group is an unsubstituted heteroCi-10 alkyl.

[0026] The term“alkenyl” refers to a radical of a straight -chain or branched hydrocarbon group having from 2 to 10 carbon atoms and one or more carbon-carbon double bonds (e.g.,

1, 2, 3, or 4 double bonds). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C2-9 alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C2-8 alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C2-7 alkenyl”).

In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C _2- e alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C2-5 alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C2-4 alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C2-3 alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C ₂ alkenyl”). The one or more carbon- carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-4 alkenyl groups include ethenyl (C ₂ ), 1-propenyl (C3), 2-propenyl (C3), 1- butenyl (C ₄ ), 2-butenyl (C ₄ ), butadienyl (C ₄ ), and the like. Examples of C2-6 alkenyl groups include the aforementioned C _2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (Ce). and the like. Additional examples of alkenyl include heptenyl (C ₇ ), octenyl (Cs), octatrienyl (C ₈ ), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an“unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents. In certain embodiments, the alkenyl group is an unsubstituted C2-10 alkenyl. In certain embodiments, the alkenyl group is a substituted C2-10 alkenyl. In an alkenyl group, a C=C double bond for which the stereochemistry is not specified (e.g., -CH=CHCH3 or ) may be an (E)- or (Z)- double bond.

[0027] The term“heteroalkenyl” refers to an alkenyl group, which further includes at least one heteroatom (e.g., 1 , 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (/.e., inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 10 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC ₂ -io alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 9 carbon atoms at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC ₂ -9 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroCb-x alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC ₂ -7 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC _2-6 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and I or 2 heteroatoms within the parent chain (“heteroC ₂ -5 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain (“heteroC ₂ -4 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, and 1 heteroatom within the parent chain (“heteroC _2-3 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain (“heteroC _2-6 alkenyl”). Unless otherwise specified, each instance of a heteroalkenyl group is independently unsubstituted (an“unsubstituted heteroalkenyl”) or substituted (a “substituted heteroalkenyl”) with one or more substituents. In certain embodiments, the heteroalkenyl group is an unsubstituted heteroC _2-i o alkenyl. In certain embodiments, the heteroalkenyl group is a substituted heteroC _2-i o alkenyl.

[0028] The term“alkynyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 10 carbon atoms and one or more carbon-carbon triple bonds (e.g., I, 2, 3, or 4 triple bonds) (“C _2-i o alkynyl”). In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C _2-9 alkynyl”). In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C _2-8 alkynyl”). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C _2- 7 alkynyl”). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C _2-6 alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C _2-5 alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C _2-4 alkynyl”). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C2-3 aikynyl”). In some

embodiments, an alkynyl group has 2 carbon atoms (“C ₂ alkynyl”). The one or more carbon- carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C _2-4 alkynyl groups include, without limitation, ethynyl (C ₂ ), l-propynyl (C ₃ ), 2- propynyl (C ₃ ), 1-butynyl (C ₄ ), 2-butynyl (C ₄ ), and the like. Examples of C _2-6 alkenyl groups include the aforementioned C _2-4 alkynyl groups as well as pentynyl (C ₅ ), hexynyl (C ₆ ), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (Cs), and the like. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an“unsubstituted alkynyl”) or substituted (a“substituted alkynyl”) with one or more substituents. In certain embodiments, the alkynyl group is an unsubstituted C _2-10 alkynyl. In certain embodiments, the alkynyl group is a substituted C _2-10 alkynyl.

[0029] The term“heteroalkynyl” refers to an alkynyl group, winch further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 10 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC ₂ -io alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC ₂ -9 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and I or more heteroatoms within the parent chain (“heteroC2- s alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC _2-7 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and I or more heteroatoms within the parent chain (“heteroC _2-6 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroCk-s alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC _2-4 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 3 carbon atoms, at least one triple bond, and 1 heteroatom within the pat ent chain (“heteroC2-3 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heleroCb-e alkynyl”). Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an“unsubstituted heteroalkynyl”) or substituted (a“substituted

heteroalkynyl”) with one or more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted heteroCe-io alkynyl. In certain embodiments, the heteroalkynyl group is a substituted heteroC2-io alkynyl.

[0030] The term“carbocyclyl” or“carbocyclic” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 14 ring carbon atoms (“C _3-14 carbocyclyl”) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 10 ring carbon atoms (“C _3-10 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C ₃ -s carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms (“C _3-7 carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C _3-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 4 to 6 ring carbon atoms (“C _4-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 6 ring carbon atoms (“Cs-e carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C _5-10 carbocyclyd”). Exemplary C _3-6 carbocyclyl groups include, without limitation, cyclopropyl (C ₃ ), cyclopropenyl (C ₃ ), cyciobutyi (C ₄ ), cyclobutenyl (C ₄ ), cyclopentyl (C ₅ ), cyclopentenyl (Cs), cyclohexyl (Cs), cyclohexenyl (C ₆ ), cyclohexadienyl (Ce), and the like. Exemplary C ₃ -s carbocyclyl groups include, without limitation, the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C ₇ ), cycloheptadienyl (C ₇ ), cycloheptatrienyl (C ₇ ), cyclooctyl (Cs), cyclooctenyl (Cs), bicyclo[2.2.1]heptanyl (C ₇ ), bicyclo[2.2.2]octanyl (Cs), and the like.

Exemplary C _3-10 carbocyclyl groups include, without limitation, the aforementioned C _3- s carbocyclyl groups as well as cyclononyl (C ₉ ), cyclononenyl (C ₉ ), cyclodecyl (C ₁₀ ), cyclodecenyl (C10), octahydro-lH-indenyl (Cs), decahydronaphthalenyl (C ₁₀ ),

spiro[4.5]decanyl (C ₁₀ ), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or can contain one or more carbon-carbon double or triple bonds.“Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently unsubstituted (an“unsubstituted carbocyclyl”) or substituted (a“substituted carbocyclyl”) with one or more substituents. In certain embodiments, the carbocyclyl group is an unsubstituted C _3-i4 carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C3-14 carbocyclyl.

[0031] In some embodiments,“carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 14 ring carbon atoms (“C3-14 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 10 ring carbon atoms (“C _3-10 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C _3-8 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C _3-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 4 to 6 ring carbon atoms (“C _4-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C5-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C _5-10 cycloalkyl”). Examples of C5-6 cycloalkyl groups include cyciopentyl (C ) and cyclohexyl (Cs). Examples of C _3-6 cycloalkyl groups include the aforementioned C _5-6 cycloalkyl groups as well as cyclopropyl (C ₃ ) and cyclobutyl (C ₄ ). Examples of C _3-8 cycloalkyl groups include the aforementioned C _3-6 cycloalkyl groups as well as cycloheptyl (C _?) and cyclooctyl (Cs). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an“unsubstituted cycloalkyl”) or substituted (a“substituted cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl group is an unsubstituted C3-14 cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C3-14 cycloalkyl.

[0032] The term“heterocyclyl” or“heterocyclic” refers to a radical of a 3- to 14-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“3-14 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and can be saturated or can contain one or more carbon- carbon double or triple bonds. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings.“Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instanc e of heterocyclyl is independently unsubstituted (an‘unsubstituted heterocyclyl”) or substituted (a“substituted heterocyclyl”) with one or more substituents. In certain embodiments, the heterocyclyl group is an unsubstituted 3-14 membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 3-14 membered heterocyclyl.

[0033] In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”). hi some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”). In some embodiments, the

5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.

[0034] Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azirdinyl, oxiranyl, and thiiranyl. Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyi, tetrahydrothiophenyl,

dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5- membered heterocyclyl groups containing 2 heteroatoms include, without limitation, dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazolinyi, oxadiazolinyl, and thiadiazolinyl. Exemplar _}' 6-membered heterocyclyl groups containing 1 heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary

6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazinyl. Exemplary 7- membered heterocyclyl groups containing 1 heteroatom include, without limitation, azepanyl. oxepanyl and thiepanyl. Exemplary- 8-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindoiinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofiiranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolmyl, decahydroisoquinolinyl, octahydrochromenyl, oclahydroisochromenyl, d e cah y d ron ap h t h yr i d i n y 1. decahydro- 1,8- naphthyridinyl, octahydropyrrolo[ 3,2-b Ipyrrole, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, lH-benzo[e][l,4]diazepinyl, l ,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl, 5 , 6-d i hy dro-4 H - i ^' uro 13,2-b | pyrrol y 1 , 6,7-dihydro-5H-furo[3,2-b]pyranyl, 5,7-dihydro-4H- thieno[2,3-c]pyranyl, 2,3-dihydro- lH-pyrrolo[2,3-b]pyridinyl, 2,3-di h ydro I ^' uro 12,3- bjpyridinyl, 4,5,6,7-tetrahydro-lH-pyrrolo[2,3-b]pyridinyl, 4,5,6,7-tetrahydrofuro[3,2- cjpyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyi, 1 ,2,3,4-tetrahydro- 1 ,6-naphthyridinyl, and the like.

[0035] The term“aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 p electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C6-14 aryl”). In some embodiments, an aryl group has 6 ring carbon atoms (“Ce aryl”; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (“C ₁₀ aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (“C ₁₄ aryl”; e.g., anthracyl).“Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of an aryl group is independently unsubstituted (an“unsubstituted aryl”) or substituted (a“substituted aryl”) with one or more substituents. In certain embodiments, the aryl group is an unsubstituted Ce- aryl. In certain embodiments, the aryl group is a substituted Ce-u aryl .

[0036] “Aralkyl” is a subset of“alkyl” and refers to an alkyl group substituted by an aryl group, wherein the point of attachment is on the alkyl moiety.

[0037] The tenn“heteroaryl” refers to a radical of a 5-14 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 p electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-14 membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings.“Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl gr oups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic (aryl/heteroaryl) ring system. Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i. e.. either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indoiyl).

[0038] In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In some embodiments, the 5- 6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (an“unsubstituted heteroaryl”) or substituted (a“substituted heteroaryl”) with one or more substituents. In certain embodiments, the heteroaryl group is an unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is a substituted 5-14 membered heteroaiyl.

[0039] Exemplary 5 -membered heteroaryl groups containing 1 heteroatom include, without limitation, pyrrolyi, furanyi, and thiophenyi. Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazoiyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing 3 heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary

5-membered heteroaryl groups containing 4 heteroatoms include, without limitation, tetrazoiyl. Exemplary 6-membered heteroaryl groups containing 1 heteroatom include, without limitation, pyridinyl. Exemplary' 6-membered heteroaryl groups containing 2 heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary

6-membered heteroaryl groups containing 3 or 4 heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing 1 heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6- bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl,

benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaiyl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include, without limitation, phenanthridinyi, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl, and phenazinyl.

[0040] “Heteroaralkyi” is a subset of“alkyl” and refers to an alkyl group substituted by a heteroaryl group, wherein the point of attachment is on the alkyl moiety.

[0041] The term“unsaturated bond” refers to a double or triple bond.

[0042] The term“unsaturated” or“partially unsaturated” refers to a moiety that includes at least one double or triple bond.

[0043] The term“saturated” refers to a moiety that does not contain a double or triple bond, /.<?., the moiety’ only contains single bonds.

[0044] Affixing the suffix“-ene” to a group indicates the group is a divalent moiety, e.g., alkylene is the divalent moiety of alkyl, alkenyiene is the divalent moiety of alkenyl, alkynylene is the divalent moiety of alkynyl, heteroalkylene is the divalent moiety of heteroalkyl, heteroalkenylene is the divalent moiety _’ of heteroalkenyl, heteroalkynylene is the divalent moiety of heteroalkynyl, carbocyclylene is the divalent moiety of carbocyclyl, heterocyciylene is the divalent moiety of heterocyclyl, arylene is the divalent moiety of aryl, and heteroarylene is the divalent moiety of heteroaryl.

[0045] A group is optionally substituted unless expressly provided otherwise. The term “optionally^ substituted” refers to being substituted or unsubstituted. In certain embodiments. alkyl, alkenyl alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted.“Optionally substituted” refers to a group which may be substituted or unsubstituted (e.g.,“substituted” or“unsubstituted” alkyl, “substituted” or“unsubstituted” alkenyl,“substituted” or“unsubstituted” alkynyl, “substituted” or“unsubstituted” heteroalkyl,“substituted” or“unsubstituted” heteroalkenyl, “substituted” or“unsubstituted” heteroalkynyl,“substituted” or“unsubstituted” carbocyclyl, “substituted” or“unsubstituted” heterocyclyl,“substituted” or“unsubstituted” aryl or “substituted” or“unsubstituted” heteroaryl group). In general, the term“substituted” means that at least one hydrogen present on a group is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a“substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term“substituted” is contemplated to include substitution with all permissible substituents of organic compounds, and includes any of the substituents described herein that results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety. The invention is not intended to be limited in any manner by the exemplary substituents described herein.

[0046] Exemplary carbon atom substituents include, but are not limited to, halogen, -CN, -N0 ₂ , -N ₃ , -S0 ₂ H, -S0 ₃ H, -OH, -OR" ¹ , -ON(R ^bb ) ₂ , -N(R ^bb ) ₂ , -N(R ^bb ) ₃ ⁺ XU -N(OR ^ec )R ^bb ,

-P(OR ^cc )v X . -P(R ^cc ) ₄ , -P(OR ^CC ) ₄ , -OP(R ^cc ) ₂ , -OP( R ^c ) ₃ X . -OP(OR ^cc ) ₂ , -OP(OR ^cc ) ₃ X . -OP(R ^ce ) ₄ , -OP(OR ^CC )4, -B(R ^aa ) ₂ , -B(OR ^CC )2, -BR ^aa (OR ^cc ), Ci-io alkyl CMO perhaloalkyl, C _2-i o alkenyl, C2-10 alkynyl, heteroCi-io alkyl, heteroC2-io alkenyl, heteroC _2-i o alkynyl C3-10 carbocyclyl, 3-14 membered heterocyclyl, Ce-14 aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R ^dd groups; wherein X is a counterion;

or two geminal hydrogens on a carbon atom are replaced with the group =0, =S, =NN(R ^bb ) ₂ , =NNR ^bb C(=0)R ^aa , =NNR ^bb C(=0)OR ^aa , =NNR ^bb S(=0) ₂ R ^aa , =NR ^bb , or =NOR“; each instance of R ^aa is, independently, selected from C MO alkyl, CMO perhaloalkyl, C2-10 alkenyl, C _2-i o alkynyl, heteroCi-10 alkyl, heteroC ₂ -io alkenyl, heleroC ₂ -io alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl C6-14 aryl, and 5-14 membered heteroaryl, or two R ^aa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl .

carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R ^dd groups;

each instance of R ^bb is, independently, selected from hydrogen, -OH, -OR ³³ , -N(R ^ce ) ₂ , -CN, -C(=0)R ^aa , -C(=0)N(R ^c ) ₂ , -C0 ₂ R ^aa , -S0 ₂ R ^aa , -C(=NR“)OR ^aa ,

-C(=NR ^CC )N(R ^cc ) ₂ , -S0 ₂ N(R ^cc ) ₂ , -S0 ₂ R ^cc , -S0 ₂ OR ^cc , -SOR“ -C(=S)N(R ^cc ) ₂ , -C(=0)SR ^cc , -C(=S)SR ^CC , -P(=0)(R ^aa ) ₂ , -P(=0)(0R ^cc ) ₂ , -P(=0)(N(R“) ₂ ) ₂ , CMO alkyl, C MO perhaloalkyl, C _2-i o alkenyl, C ₂ -io alkynyl, heteroCi-io alkyl, heteroC _2-i o alkenyl, heteroC _2-i oalkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, Co-14 aryl, and 5-14 membered heteroaryl, or two R ^bb groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R ^dd groups; wherein X is a counterion;

each instance of R ^cc is, independently, selected from hydrogen, CMO alkyl, CMO perhaloalkyl, C _2-i o alkenyl, C _2-i o alkynyl, heteroCi-10 alkyl, heteroC ₂ -io alkenyl, heteroC _2-i o alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl Co- 14 aryl, and 5-14 membered heteroaryl, or tw o R ^cc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl. heterocyclyl aryl, and heteroaryl is independently substituted with 0, 1 , 2, 3, 4, or 5 R ^dd groups;

each instance of R ^dd is, independently^ selected from halogen, -CN, -N0 ₂ , -N3, -S0 ₂ H, -SO3H, -OH, -OR ^ee , -ON(R ^ff ) ₂ , -N(R ^ff ) ₂ , -N(R ^ff ) ₃ XXC -N(OR“)R ^ff , -SH, -SR ^ee ,

-P(=0)(0R ^ee ) ₂ , -P(=0)(R ^ee ) ₂ , -0P(=0)(R ^ee ) ₂ , -0P(=0)(0R ^ee ) ₂ , Ci-e alkyl, Ci _-6 perhaloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, heteroCi-e alkyl, heteroC _2-6 alkenyl, keteroC _2-6 alkynyl, C _3-i o carbocyclyl, 3-10 membered heterocyclyl, Ce-io aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R ^ss groups, or two geminal R ^dd substituents can be joined to form =0 or =S: wherein X is a counterion;

each instance of R ^ee is, independently, selected from Ci-e alkyl, Ci- ₆ perhaloalkyl, C2-6 alkenyl, C _2-6 alkynyl, heteroCi- ₆ alkyl, heteroC _2-6 alkenyl, heteroC _2-6 alkynyl, C _3-i o carbocyclyl, Ce-io aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaiyl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R ^gg groups;

each instance ofR ^ff is, independently, selected from hydrogen, Ci-6 alkyl, Ci-e perhaloalkyl, C _2-6 alkenyl, C _2-6 alkynyl, heteroCi-e alkyl, heteroC ₂ -e alkenyl, heteroC ₂ -6 alkynyl, C _3-i o carbocyclyl, 3-10 membered heterocyclyl, Ce-io aryl and 5-10 membered heteroaiyl, or two R ^ff groups are j oined to form a 3- 10 membered heterocyclyl or 5 - 10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R ^sg groups; and

each instance of R ^gg is, independently, halogen, -CN, -N0 ₂ , -N ₃ , -S0 ₂ H, -S0 ₃ H, -OH, -OCi-6 alkyl, -ON(CI _-6 alkyl) ₂ , -N(CI _-6 alkyl) ₂ , -NtCi-e alkyD.f X . -NH(CI-6 alkyl) ₂ X , -NH ₂ (Ci- ₆ alkyl) X . -NHX X , -N(OC _I-6 alkyl)(Ci- ₆ alkyl), -N(OH)(C _I-6 alkyl), -NH(OH), -SH, -SC1-6 alkyl, -SS(Ci _-6 alkyl), -C(=0)(Ci- ₆ alkyl), -C0 ₂ H, -C0 ₂ (Ci _-6 alkyl), -OC(=0)(Ci. ₆ alkyl), -0C0 ₂ (Ci- ₆ alkyl), -C(=0)N¾, -C(=0)N(Cw alkyl) ₂ , -OC(=0)NH(CI-6 alkyl), -NHC(=0)(C _!-6 alkyl), -N(C _W alkyl)C(=0)( C _!-6 alkyl),

-NHC0 ₂ (CI _-6 alkyl), -NHC(=0)N(Ci _-6 alkyl) ₂ , - HC(=0)NH(CI-6 alkyl), -NHC(=0)NH _2, -C(=NH)0(CI-6 alkyl), -OC(=NH)(CI _-6 alkyl), -OC(=NH)OCI _-6 alkyl, -C(=NH)N(CI- ₆ alkyl) ₂ , -C(=NH)NH(C _I-6 alkyl), -C(=NH)NH ₂ , -OC(=NH)N(C _I-6 alkyl) ₂ , -OC(=NH)NH(CI-6 alkyl), -OC(=NH)NH ₂ , -NHC(=NH)N(CI-6 alkyl) , -NHC(=NH)NH ₂ , -NHS0 ₂ (CI- ₆ alkyl), -S0 ₂ N(C|. _fi alkyl) ₂ , -S0 ₂ NH(Ci _-6 alkyl), -S0 ₂ NH ₂ , -S0 ₂ (Ci- ₆ alkyl), -S0 ₂ 0(Ci-6 alkyl), -0S0 ₂ (Ci- ₆ alkyl), -SO(Ci- ₆ alkyl), -Si(C _!-6 alkyl) ₃ , -OSi(Ci- ₆ alkyl) ₃ -C(=S)N(CI-6 alkyl) ₂ , C(=S)NH(C _1-6 alkyl), C(=S)NH _{¾ -} C(=0)S(Ci _-6 alkyl), -C(=S)SCi _-6 alkyl, -SC(=S)SCi-6 alkyl, -P(=0)(0Ci-6 alkyl) ₂ , -P(=0)(Ci- ₆ alkyl) , -0P(=0)(Ci _-6 alkyl) ₂ , -0P(=0)(0Ci-6 alkyl)?, Ci-6 alkyl, Ci-e perhaloalkyi, C ₂ -s alkenyl, C ₂ -6 alkynyi, heteroCi-e alkyl, heteroC _2-6 alkenyl, heteroC _2-6 alkynyi, C3-10 carbocyclyl, Ce-io aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal R ^sg substituents can be joined to form =0 or =S; wherein X is a counterion.

[0047] The term“halo” or“halogen” refers to fluorine (fluoro, -F), chlorine (chioro,—Cl), bromine (bromo, -Br), or iodine (iodo, -I).

[0048] The term“hydroxyl” or“hydroxy” refers to the group -OH. The temi“substituted hydroxyl” or“substituted hydroxyl,” by extension, refers to a hydroxyl group wherein the oxygen atom directly attached to the parent molecule is substituted with a group other than hydrogen, and includes groups selected from -OR ^aa , -ON(R ^bb ) ₂ , -OC(=0)SR ^aa ,

wherein X . R ^aa , R ^bb , and R ^cc are as defined herein.

[0049] The tenn“amino” refers to the group -NH ₂ . The term“substituted amino,” by extension, refers to a monosubstituted amino, a disubstituted amino, or a trisubstituted amino. In certain embodiments, the“substituted amino” is a monosubstituted amino or a

disubstituted amino group.

[0050] The term“monosubstituted amino” refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with one hydrogen and one group other than hydrogen, and includes groups selected from -NH(R ^bb ), -NHC(=0)R ^aa ,

-NHC0 ₂ R ^aa , -NHC(=0)N(R ^bb ) ₂ , -NHC(=NR ^bb )N(R ^bb ) ₂ , -NHS0 ₂ R ^aa . -NHP(=0)(OR ^cc ) ₂ , and -NHP(=0)(N(R ^bb ) ₂ ) ₂ , wherein R ^aa , R ^bb and R ^cc are as defined herein, and wherein R ^bb of the group -NH(R ^bb ) is not hydrogen.

[0051] The term“disubstituted amino” refers to an amino group wherein the nitrogen atom directly' attached to the parent molecule is substituted with two groups other than hydrogen, and includes groups selected from -N(R ^bb ) ₂ , -NR ^bb C(=0)R ^aa , -NR ^bb C0 ₂ R ^aa ,

-NR ^bb C(=0)N(R ^bb ) , -NR ^bb C(=NR ^bb )N(R ^bb ) ₂ , -NR ^bb S0 ₂ R ^aa , -NR ^bb P(=0)(OR ^cc ) ₂ , and -NR ^bb P(=0)(N(R ^bb ) ₂ ) ₂ , wherein R ^aa , R ^bb , and R ^cc are as defined herein, with the proviso that the nitrogen atom directly attached to the parent molecule is not substituted with hydrogen.

[0052] The term“trisubstituted amino” refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with three groups, and includes groups selected from -N(R ^bb )3 and -N(R ^bb )f X . wherein R ^bb and X are as defined herein.

[0053] The term“sulfonyl” refers to a group selected from -S02N(R ^bh )2, -SO R ^aa , and - SCTOR ³³ , wherein R ^aa and R ^bb are as defined herein.

[0054] The term“sulimyl” refers to the group -S(=0)R ^aa , wherein R ^aa is as defined herein.

[0055] The term“acyl” refers to a group having the general formula -C(=0)R ^X1 ,

-C(=0)OR ^xl , -C(=0)-0-C(=0)R ^xl , -C(=0)SR ^X1 , -C(=0)N(R ^X1 ) ₂ , -C(=S)R ^X1 ,

-C(=S)N(R ^x1 ) ₂ , -C(=S)0(R ^X! ), -C(=S)S(R ^X1 ), -C(=NR ^X1 )R ^X1 , -C(=NR ^X1 )OR ^X! ,

-C(=NR ^X1 )SR ^X1 , and -C(=NR ^XI )N(R ^X1 ) ₂ , wherein R ^X! is hydrogen; halogen; substituted or unsubstituted hydroxyl; substituted or unsubstituted thiol; substituted or unsubstituted amino; substituted or unsubstituted acyl, cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy,

heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, mono- or di- aliphaticamino, mono- or di- heteroaliphaticamino, mono- or di- alkylamino, mono- or di- heteroalkylamino, mono- or di-arylamino, or mono- or di-heteroarylamino; or two R ^Xi groups taken together form a 5- to 6-membered heterocyclic ring. Exemplary acyl groups include aldehydes (-CHO), carboxylic acids (-CO2H), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas. Acyl substituents include, but are not limited to, any of the substituents described herein, that result in the formation of a stable moiety (e.g., aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl, acyl, oxo, imino, thiooxo, cyano, isocyano, amino, azido, nitro, hydroxyl, thiol, halo, aliphaticamino, heteroaliphaticamino, alkylamino, heteroalkylamino, arylamino, heteroarylamino, alkylaryl, arylalkyl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, acyloxy, and the like, each of which may or may not be further substituted). [0056] The term“carbonyl” refers a group wherein the carbon directly attached to the parent molecule is sp ² hybridized, and is substituted with an oxygen, nitrogen or sulfur atom, e.g., a group selected from ketones (e.g., -C(=0)R ^aa ). carboxylic acids (e.g. , -C0 ₂ H), aldehydes (-CHO), esters ( e.g ., -C0 ₂ R ^aa ,-C(=0)SR ^aa , -C(=S)SR ^aa ), amides (e.g., - C(=0)N(R ^bb ) ₂ , -C(=0)NR ^bb S0 ₂ R ^aa , -C(=S)N(R ^bb ) ₂ ), and imines (e.g., -C(=NR ^bb )R ^aa , - C(=NR ^bb )OR ^aa ), -C(=NR ^bb )N(R ^bb ) ₂ ), wherein R ^aa and R ^bb are as defined herein.

[0057] The term“silyl” refers to the group -Si( R ^aa T, wherein R ^aa is as defined herein.

[0058] The term“oxo” refers to the group =0, and the term“thiooxo” refers to the group =S.

[0059] Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, -OH, -OR ^aa , -N(R ^CC ) ₂ , -CN,

-C(=0)R ^aa , -C(=0)N(R ^cc ) ₂ , -C0 ₂ R ^aa , -S0 ₂ R ^1,a , -C(=NR ^bb )R“ -C(=NR ^ce )OR ^aa ,

-C(=NR ^CC )N(R ^cc ) ₂ , -S0 ₂ N(R ^cc ) _{2, -} S0 ₂ R ^cc , -S0 ₂ OR ^cc , -SOR ^aa , -C(=S)N(R ^cc ) _{2, -} C(=0)SR“, -C(=S)SR ^¥ , -P(=0)(OR ^cc ) ₂ , -P(=0)(R ^aa ) ₂ , -P(=0)(N(R ^cc ) ₂ ) ₂ , CMO alkyl, Ci-10 perhaloalkyl, C _2-i o alkenyl, C _2-i o alkynyl, heteroCi-ioalkyl, heteroC _2-i oalkenyl, heteroC ₂ -ioalkynyl, Cs-io carbocyclyl, 3-14 membered heterocyclyl, Ce-14 aryl, and 5-14 membered heteroaryl, or two R ^cc groups attached to an N atom are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R ^dd groups, and wherein R ^aa , R ^bb , R ^c , and R ^dd are as defined herein.

[0060] In certain embodiments, the substituent present on the nitrogen atom is an nitrogen protecting group (also referred to herein as an“amino protecting group”). Nitrogen protecting groups include, but are not limited to, -OH, -OR ³³ , -N(R ^CC ) ₂ , -C(=0)R ^aa , -C(=0)N(R ^ce ) ₂ , -C0 ₂ R ^aa , -S0 ₂ R ^aa , -C(=NR ^cc )R ^aa , -C(=NR“)OR ^aa , -C(=NR ^CC )N(R ^CC ) ₂ , -S0 ₂ N(R ^cc ) ₂ , -S0 ₂ R ^cc , -S0 ₂ OR ^cc , -SOR ^aa , -C(=S)N(R ^¥ ) ₂ , -C(=0)SR ^cc , -C(=S)SR ^cc , CMO alkyl (e.g , aralkyl, heteroaralkyl), C _2-i o alkenyl, C2-10 alkynyl, heteroCi-10 alkyl, heteroC ₂ -io alkenyl, heteroC _2-i o alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, Ce-i4 aryl, and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, heteroalkyl,

heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R ^dd groups, and wherein R ^aa , R ^bb , R ^cc and R ^dd are as defined herein. Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis , T. W. Greene and P. G. M. Wuts, 3 ^rd edition, John Wiley & Sons, 1999, incorporated herein by reference. [0061] For example, nitrogen protecting groups such as amide groups (e.g. , -C(=0)R ^aa ) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picoiinamide, 3- pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o- nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N’- dithiobenzyloxyacyiamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o- nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2 -methyl-2-(o- phenylazophenoxylpropanamide, 4-chlorobutanamide, 3 -methyl-3 -nitrobutanamide, o- nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide, and o- (benzoyloxymethyl)benzamide.

[0062] Nitrogen protecting groups such as carbamate groups (e.g., -C(=0)OR ^aa ) include, but are not limited to, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(l 0, 10-dioxo- 10, 10, 10, 10-tetrahydrothioxanthyl)]methyl carbamate (DBD- Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2 -trichloroethyl carbamate (Troc), 2- trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), l-(l-adamantyl)-l- methylethyl carbamate (Adpoc), 1 , 1 -dimethyl-2-haloethyl carbamate, l,l-dimethyi-2,2- dibromoethyl carbamate (DB-t-BOC), 1,1 -dimethyl-2 ,2 ,2-trichloroethyl carbamate

(TCBOC), 1 -methyl- l-(4-biphenylyl)ethyl carbamate (Bpoc), l-(3,5-di-t-butylphenyl)-l- methylethyl carbamate (t-Brmieoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N- dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC or Boc), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), ally! carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyi carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate, p- chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsuifin\4benzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsu fonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(l,3- dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4- dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2- triphenylphosphonioisopropyl carbamate (Ppoc), 1 , 1 -dimethyl-2-cyanoethyl carbamate, m- chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5- benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmeth\4 carbamate (Tcroc), m-nitropheny carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4- dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, t-amy carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p- decyloxybenzyl carbamate 2,2-dimethoxyacylviny carbamate, o-(N,N- dimethylcarboxamido)benzyl carbamate, 1 , 1 -dimethyi-3-(N,N-dimethylcarboxamido)propyl carbamate, 1 ,1 -dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p’-methoxyphenylazo)benzyi carbamate, 1-methylcyclobutyl carbamate, 1- methylcyclohexyl carbamate, 1 -methyl- 1 -cyclopropylmethyl carbamate, 1 -methyl- 1 -(3,5- dimethoxyphenyl)ethyl carbamate, 1 -methyl- l-(p-phenylazophenyl)ethyl carbamate, 1- methyl-l-phenylethyl carbamate, 1 -methyl- l-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4- (trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.

[0063] Nitrogen protecting groups such as sulfonamide groups (e.g., -S(=0) ₂ R ^aa ) include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4- methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6- dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3 ,5,6-tetramethyl-4- methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6- trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methyibenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), b- trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8'- dimethoxynaphthylmethyi)benzenesulfonamide (DNMBS), benzylsuifonamide,

trifluoromethylsulfonamide, and phenacylsulfonamide.

[0064] Other nitrogen protecting groups include, but are not limited to, phenothiazinyl- (lO)-acyl derivative, N'-p-toluenesulfonylaminoacyl derivative, N'-phenylaminothioacyl derivative, N-benzoylphenylalany derivative, N-acetylmethionine derivative, 4,5-diphenyl-3- oxazolin-2-one, N-phthaiimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5- dimethylpyrrole, N-l,l,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5- substituted 1 , 3-dimethyl- 1, 3, 5-triazacyclohexan-2-one, 5-substituted 1, 3 -dibenzyl- 1,3,5 - triazacyclohexan-2-one, 1 -substituted 3,5-dinitro-4-pyridone, N-methylamine, N-aliylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(l-isopropyl- 4-nitro-2-oxo-3-p\Toolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4- methoxyphenyl)methylamine, N-5-di ben/osubery la i ne, N-triphenylmethylamine (Tr), N- [(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N- 2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenyimethylamino (Fcm), N-2- picolylamino N '-oxide, N-l ,l-dimethylthiomethyleneamine, N-benzylideneamine, N-p- methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2- pyridyi)mesityl]methyleneamine, N-(N’,N’-dimethylaminomethyiene)amine, N,N'- isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5- chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyi )pheny] methyleneamine, N- cyclohexylideneamine, N-(5,5-dimethyl-3-oxo- 1 -cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-[phenyl(pentaacylchromium- or tungsten)acyl] amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt),

diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4- dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4- methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys). In certain embodiments, a nitrogen protecting group is benzyl (Bn), tert- butyloxycarbonyl (BOC), carbobenzyloxy (Cbz), 9-flurenylmethyloxycarbonyl (Fmoc), trifluoroacetyl, triphenylmethyl, acetyl (Ac), benzoyl (Bz), p-methoxybenzyl (PMB), 3,4- dimethoxybenzyl (DMPM), p-methox fhenyl (PMP), 2,2,2-trichloroethyloxycarbonyl (Troc), triphenylmethyl (Tr), tosyl (Ts), brosyl (Bs), nosyl (Ns), mesyl (Ms), triflyl (Tf), or dansyl (Ds).

[0065] In certain embodiments, the substituent present on an oxygen atom is an oxygen protecting group (also referred to herein as an“hydroxyl protecting group”). Oxygen protecting groups include, but are not limited to, -R ^aa , -N(R ^bb ) ₂ , -C(=0)SR ^aa , -C(=0)R ^aa , -C0 ₂ R ^aa ,— C(=0)N(R ^bb ) ₂ ,— C (=NR ^bb )R ^aa , -C(=NR ^bb )OR ^aa , -C(=NR ^bb )N(R ^bb ) ₂ , -S(=0)R ^aa , -S0 ₂ R ^aa , -Si(R ^aa ) ₃ , -P(R ^cc ) ₂ , -P(R ^CC ) ₃ ⁺ XT -P(OR ^cc ) ₂ , -P(OR ^LC )I X , -P(=0)(R“) ₂ , -P(=0)(0R ^cc ) ₂ , and -P(=0)(N(R ^bb ) ₂ ) ₂ , wherein X , R ^aa , R ^bb , and R ^cc are as defined herein. Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 ^rd edition, John Wiley & Sons, 1999, incorporated herein by reference.

[0066] Exemplary oxygen protecting groups include, but are not limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl,

(phenyldimethylsilyi)methoxymethyl (SMOM), benzyloxymethyl (BOM), p- methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2- methoxyethoxymethyl (MEM), 2,2,2 -trichloroethoxymethyl, b i s (2 -c h I o ro e ί h o x ) met h y 1 , 2- (trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3- br o m o t e trahy d rop yran y I , tetrahydrothiopyranyl, 1 -methoxycyclohexyl, 4- methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4- methoxytetrahydrothiopyranyl S,S-dioxide, l-[(2-chloro-4-methyl)phenyl]-4- methoxypiperidin-4-yl (CTMP), l,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzo furan-2-yl, 1 -ethoxyethyl, 1 - (2-chloroethoxy)ethyl, 1 -methyl- 1 -methoxyethyl, 1 -methyl- 1 -benzyloxyethyl, 1 -methyl- 1 - benzyloxy-2-fluoroethyl, 2,2,2-trichloroethy , 2-trimethylsi ylethyl, 2-(phenylselenyl)ethyl, t- buty , ally!, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p- methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzy , 2,6- dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N- oxido, diphenylmethyl, p,p’-dimtrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, a- naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p- methoxyphenyi)phenyimethyl, tri(p-methoxyphenyl)methyl, 4-(4’- bromophenacyloxyphenyl)diphenylmethyl, 4,4',4"-tris(4,5- dichlorophthalimidophenyl)methyl, 4,4',4''-tris(levulinoyloxyphenyl)methyl, 4,4',4"- tris(benzoyloxyphenyl)methyl, 3-(imidazol-l -yi)bis(4',4"-dimethoxyphenyi)methyl, 1,1- bis(4-methoxyphenyl)- 1 '-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10- oxo)anthryl, l,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS),

diethylisopropyisilyl (DEIPS), dimethylthexylsilyl, t-butyldimethy sily (TBDMS), t- butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsi yl, triphenylsilyl,

diphenylmethylsilyl (DPMS), t-buty methoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4- oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6- trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethy carbonate (Fmoc), ethyl carbonate, 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), isobutyl carbonate, vinyl carbonate, ally! carbonate, t-butyl carbonate (BOC or Boc), p- nitrophenyl carbonate, benzyl carbonate, p-methoxybenzyl carbonate, 3,4-dimethoxybenzyl carbonate, o-nitrobenzyl carbonate, p-nitrobenzyl carbonate, S-benzyl thiocarbonate, 4- ethoxy-l-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4- nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2- (methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-

(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4- (1,1 ,3,3-tetramethylbutyi)phenoxyacetate, 2,4-bis(l, l-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate monosuccinoate, (E)-2-methyl-2-butenoate, o- (methoxyacyl)benzoate, a-naphthoate, nitrate, alkyl N,N,N’,N’- tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyi, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). In certain embodiments, an oxygen protecting group is silyl. In certain embodiments, an oxygen protecting group is t-butyidiphenylsi yl (TBDPS), t- butyldimethylsilyl (TBDMS), triisoproylsilyl (TIPS), triphenylsilyl (TPS), triethylsilyl (TES), trimethylsilyl (TMS), triisopropylsiloxymethyl (TOM), acetyl (Ac), benzoyl (Bz), allyl carbonate, 2,2,2-trichloroethyl carbonate (Troc), 2 -tri ethyl s i I yl elh y 1 carbonate,

methoxymethyl (MOM), 1 -ethoxyethy! (EE), 2-methyoxy-2-propyl (MOP), 2,2,2- trichloroethoxyethyl, 2-methoxyethoxymethyl (MEM), 2-trimeth\isilylethoxymethyl (SEM), methylthiomethyl (MTM), tetrahydropyranyl (THP), tetrahydrofuranyl (THF), p- methoxyphenyl (PMP), triphenylmethyl (Tr), methoxytrityl (MMT), dimethoxytrityl (DMT), allyl, p-methoxybenzyl (PMB), t-butyl, benzyl (Bn), allyl, or pivaloyl (Piv).

[0067] In certain embodiments, the substituent present on a sulfur atom is a sulfur protecting group (also referred to as a“thiol protecting group”). Sulfur protecting groups include, but are not limited to, -R ^aa , -N(R ^bb ) ₂ , -C(=0)SR ^1,a , -C(=0)R ^aa , -C0 ₂ R ^aa ,

-C(=0)N(R ^bb ) ₂ , -C(=NR ^bb )R ^aa , -C(=NR ^bb )OR ^aa , -C(=NR ^bb )N(R ^bb ) ₂ , -S(=0)R ^aa , -S0 ₂ R ^aa , -Si(R ^aa ) ₃ , -P(R ^cc ) ₂ , -P(R ^CC )3 ⁺ X , -P(OR ^cc ) ₂ , -P(OR ^CC ) ₃ ⁺ X , -P(=0)(R ^aa ) ₂ , -P(=0)(0R ^cc ) ₂ , and -P(=0)(N(R ^bb ) ₂ ) ₂ , wherein R ^aa , R ^bh , and R ^cc are as defined herein. Sulfur protecting groups are w'ell known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 ^rd edition, John Wiley & Sons, 1999, incorporated herein by reference. In certain embodiments, a sulfur protecting group is acetamidomethyi, t-Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine-sulfenyl, or triphenylmethyl.

[0068] A“counterion” or“anionic counterion” is a negatively charged group associated with a positively charged group in order to maintain electronic neutrality. An anionic counterion may be monovalent (i.e., including one formal negative charge). An anionic counterion may also be multivalent (/.<?., including more than one formal negative charge), such as divalent or trivalent. Exemplary cormterions include halide ions (e.g., F , Cl , Br , G), NO;C, OO4 , OH-, H2PO4 , HCO3 HS0 _{4 ,} sulfonate ions (e.g., methansulfonate,

trifluoromethanesul fonate, oluenesulfonate, benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene- 1 -sulfonic acid-5-sulfonate, ethan-l -sulfonic acid- 2-sulfonate, and the like), carboxylate ions (e.g., acetate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, gluconate, and the like), BF4 PF4 , PF ₆ , AsF ₆ , SbF ₆ - B[3,5- (CF3) ₂ C6H3] ₄ ]- BCCeFsK, BPh ₄ , Al(OC(CF ₃ )3)4ri and carborane anions (e.g., CBnHiT or (HCBn MesBr _f ,) ) Exemplary counterions which may be multivalent include COr , HPO4 ² , PO4 ³ _, B ₄ 0 ₇ ² , S0 ₄ ² . S2O; ² , carboxylate anions (e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like), and carboranes.

[0069] The term“leaving group” is given its ordinary meaning in the art of synthetic organic chemistry and refers to an atom or a group capable of being displaced by a nucleophile. See, for example, Smith, March 's Advanced Organic Chemistry 6th ed. (501- 502). Examples of suitable leaving groups include, but are not limited to, halogen (such as F, Cl, Br, or I (iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy, alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g. , aeetoxy), arylcarbonyloxy, aryloxy, methoxy, 7V,0-dimethylhydroxylamino, pixyl, and haloformates. hl some cases, the leaving group is a sulfonic acid ester, such as toluenesulfonate (tosylate, -OTs), methanesulfonate (mesylate, - OMs), />bromobenzenesulfonyloxy (brosylate, -OBs), -OS(=0) ₂ (CF ₂ ) ₃ CF ₃ (nonaflate, -ONf), or trifluoromethanesu lfonate (triflate, -OTf). In some cases, the leaving group is a brosylate, such as /?-bromobenzenesulfonyloxy. In some cases, the leaving group is a nosylate, such as 2-nitrobenzenesulfonyioxy. The leaving group may also be a phosphineoxide (e.g. , formed during a Mitsunobu reaction) or an internal leaving group such as an epoxide or cyclic sulfate. Other non-limiting examples of leaving groups are water, ammonia, alcohols, ether moieties, thioether moieties, zinc halides, magnesium moieties, diazonium salts, and copper moieties. Further exemplary leaving groups include, but are not limited to, halo (e.g., chloro, bromo, iodo) and activated substituted hydroxyl groups (e.g. , -OC(=0)SR ^a ', -OC(=0)R ^aa , - OCCTRA -OC(=0)N(R ^bb ) ₂ , -OC(=NR ^bb )R ^aa , -OC(=NR ^bb )OR ^aa , -OC(=NR ^bb )N(R ^bb ) ₂ , - OS(=0)R ^aa , -OS0 ₂ R ^aa , -OP(R ^cc ) ₂ , -OP(R ^cc ) ₃ , -OP(=0) ₂ R ^aa , -OP(=0)(R ^aa ) ₂ , - 0P(=0)(0R“) ₂ , -OP(=0) ₂ N (R ^bb ) _{2 ,} and -OP(=0)(NR ^bb ) ₂ , wherein R ^aa , R ^bb , and R ^cc are as defined herein). [0070] As used herein, use of the phrase“at least one instance” refers to 1, 2, 3, 4, or more instances, but also encompasses a range, e.g., for example, from 1 to 4, from 1 to 3, from 1 to 2, from 2 to 4, from 2 to 3, or from 3 to 4 instances, inclusive.

[0071] A“non-hydrogen group” refers to any group that is defined for a particular variable that is not hydrogen.

[0072] These and other exemplary substituents are described in more detail in the Detailed Description, Examples, and claims. The invention is not intended to be limited in any manner by the above exemplary listing of substituents.

Other definitions

[0073] The following definitions are more general terms used thr oughout the present application.

[0074] As used herein, the terms“amplify” and“amplification” as used herein means amplification of reporter signal.

[0075] As used herein, the term“deposition” means directed binding of a reactive intermediate to the receptor which results from the formation of a covalent bond.

[0076] As used herein, the term“reactive intermediate” means the substrate portion of the conjugate has been primed by the enzyme to bind to the receptor. In the compounds of the disclosure, the phenolic moiety is converted to the reactive intermediate, which can bind to the receptor.

[0077] As used herein, the term“salt” refers to any and all salts, and encompasses pharmaceutically acceptable salts.

[0078] The term“pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.

Pharmac eutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyciopentanepropionate, digluconate, dodecylsuifate,

ethanesulfonate, formate, fumarate, giucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesuifonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N ⁺ (Ci-4 alkylfr salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.

[0079] The term“solvate” refers to forms of the compound, or a salt thereof, that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The compounds described herein may be prepared, e.g., in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid.“Solvate” encompasses both solution-phase and isolatable solvates.

Representative solvates include hydrates, ethanolates, and methanolates.

[0080] The term“hydrate” refers to a compound that is associated with water. Typically, the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula R x FhO, wherein R is the compound, and x is a number greater than 0. A given compound may form more than one type of hydrate, including, e.g., monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R-0.5 H2O)), and polyhydrates (x is a number greater than 1, e.g., dihydrates (R-2 H2O) and hexahydrates (R-6 H2O)). [0081] The term“tautomers” or“tautomeric” refers to two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base. Exemplary tautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim, enamine-to-imine, and enamine-to-(a different enamine) tautomerizations.

[0082] It is also to be understood that compounds that have the same molecular formula but differ in the natur e or sequence of bonding of their atoms or the arrangement of their atoms in space are termed“isomers”. Isomers that differ in the arrangement of their atoms in space are termed“stereoisomers”.

[0083] Stereoisomers that are not mirror images of one another are termed“diastereomers” and those that are non-superimposable mirror images of each other are termed“enantiomers”. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a“racemic mixture”.

[0084] The term“polymorph” refers to a crystalline form of a compound (or a salt, hydrate, or solvate thereof). All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Various polymorphs of a compound can be prepared by crystallization under different conditions.

[0085] The term“biological sample” refers to any sample including tissue samples (such as tissue sections and needle biopsies of a tissue); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); samples of whole organisms (such as samples of yeasts or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise). Other examples of biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (e.g., obtained by a surgical biopsy or needle biopsy), nipple aspirates, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.

[0086] The term“tissue” refers to any biological tissue of a subject (including a group of cells, a body part, or an organ) or a part thereof, including blood and/or lymph vessels, which is the object to which a compound, particle, and/or composition of the invention is delivered. A tissue may be an abnormal or unhealthy tissue, which may need to be treated. A tissue may also be a normal or healthy tissue that is under a higher than normal risk of becoming abnormal or unhealthy, which may need to be prevented. In certain embodiments, the tissue is the central nervous system. In certain embodiments, the tissue is the brain.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

[0087] Provided herein are compounds, salts, and chelate complexes that are useful in methods of catalyzed reporter deposition for detection of analytes in biological samples. In one aspect, the disclosure provides compounds of Formula (I), and salts, chelate complexes, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. In certain embodiments, the disclosure provides chelate complexes comprising the compounds of Formula (I) and a metal cation.

Compounds

[0088] The compounds described herein possess hydrogen donating moieties that can be oxidized when contacted with an enzyme activation system (e.g., a peroxidase). The oxidized compound is useful in methods of catalyzed reporter deposition for the detection of analytes in biological samples. In particular, the macrocyclic DOTA moiety functions as a reporter group which can be detected by a variety of detection methods (e.g., mass spectrometry based imaging). The compounds are particularly useful in the methods and uses described herein when the DOTA moiety comprises a chelate complex having a metal counterion (e.g., lanthanides, yttrium, praesodynium). The DOTA-containing compounds and complexes are advantageous over existing reporter compounds and complexes because the DOTA moiety allows detection of the reporter moiety by use of mass spectrometry imaging microscopy. A compound may be provided for use in any composition, kit, or method described herein as a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof.

[0089] In one aspect, disclosed is a compound of Fomiula (I):

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein:

G is a chelating moiety;

R ¹ is substituted or unsubstituted alkylene, a bond, -0-, -S-, or -NR ^A -;

R ² is a bond, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocycly!ene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;

X ^! is a bond or N;

X is O or S;

R- ¹ is hydrogen, substituted or unsubstituted Ci-Ce alkyl or a nitrogen protecting group;

R ⁴ is substituted or unsubstituted C -Ce heteroaliphatic, substituted or unsubstituted C2-C6 alkylene, substituted or unsubstituted C2-C6 alkenylene, or substituted or unsubstituted C2-C6 alkynylene;

R ⁵ is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl . substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A ) ₂ , or -OR ^A ;

R ⁶ is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl , substituted or unsubstituted heteroaryl, -N(R ^A ) ₂ , or -OR ⁴ ;

R ⁷ is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl substituted or unsubstituted heteroaryl, -N(R ^A ) ₂ , or -0R ^A ;

R ⁸ is hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A ) ₂ , or -OR ^A ; and

each occurrence of R ^A is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to a nitrogen atom, or two R ^A groups are joined to form a substituted or unsubstituted heterocyclic ring.

Group G

[0090] Chelation is a type of bonding of ions and molecules to metal ions. It involves the formation or presence of coordinate bonds between a ligand and a single central atom. In certain embodiments, the ligand may be polydentate, or multiply bonded. Typically, these ligands are organic compounds, and are called chelants, chelators, chelating agents, or sequestering agents.

[0091] As generally defined herein, G is a chelating moiety. In certain embodiments, G comprises amino acid moieties that act as chelating atoms. In certain embodiments, G is a heterocyclic moiety. In certain embodiments, G is an acyclic moiety. In certain embodiments, G is capable of forming a chelate complex with a metal ion.

[0092] In certain embodiments, G is of the formula

[0093] In certain embodiments, G is of the formula

Group R

[0094] As generally defined herein, R ¹ is substituted or unsubstituted alkylene, a bond, -0-, -S-, or -NR ^a -. In certain embodiments, R ¹ is substituted or unsubstituted alkylene. In certain embodiments, R ¹ is substituted or unsubstituted C1-C6 alkylene. In certain embodiments, R ¹ is unsubstituted Ci-Ce alkylene. In certain embodiments, R ¹ is unsubstituted C ₁ -C ₅ alkylene. In certain embodiments, R ¹ is unsubstituted C ₁ -C ₄ alkylene. In certain embodiments, R ¹ is unsubstituted C1-C3 alkylene. In certain embodiments, R ¹ is unsubstituted C1-C2 alkylene. In certain embodiments, R ¹ is methylene. In certain embodiments, R ¹ is ethylene. In certain embodiments, R ^! is propylene. In certain embodiments, R ¹ is butylene. In certain

embodiments, R ^! is pentylene. In certain embodiments, R ¹ is hexylene.

Group R ²

[0095] As generally defined herein, R ² is a bond, substituted or unsubstituted

carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene. In certain embodiments, R ² is substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene. In certain embodiments, R ² is substituted or unsubstituted carbocyclylene. In certain embodiments, R ² is substituted or unsubstituted heterocyclylene. In certain embodiments, R ² is substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene. In certain embodiments, R ² is substituted or unsubstituted arylene. In certain embodiments, R ² is unsubstituted arylene. In certain embodiments, R ² is substituted or unsubstituted phenylene. In certain embodiments, R ² is unsubstituted phenylene.

[0096] In certain embodiments, R ¹ is substituted or unsubstituted Ci-Ce alkylene and R ² is substituted or unsubstituted phenylene. In certain embodiments, R ^! is unsubstituted C ₁ -C6 alkylene and R ² is unsubstituted phenylene.

Groups X and X ¹ [0097] As generally defined herein, X is O or S. In certain embodiments, X is O. In certain embodiments, X is S.

[0098] In certain embodiments, R ¹ is substituted or unsubstituted G-G alkylene; R ² is substituted or unsubstituted phenylene; and X is O. In certain embodiments, R ¹ is unsubstituted C1-C6 alkylene; R ² is unsubstituted phenylene; and X is O.

[0099] In certain embodiments, R ¹ is substituted or unsubstituted Ci-Ce alkylene; R ² is substituted or unsubstituted phenylene; and X is S. In certain embodiments, R ¹ is

unsubstituted G-G alkylene; R ² is unsubstituted phenylene; and X is S.

[00100] As generally defined herein, X ¹ is a bond or N. In certain embodiments, X ^! is A bond. In certain embodiments, X ¹ is N.

Group R ³

[00101] As generally defined herein, R ³ is hydrogen, substituted or unsubstituted C1-C6 alkyl, or a nitrogen protecting group. In certain embodiments, R ³ is substituted or unsubstituted G-G alkyl. In certain embodiments, R ³ is unsubstituted C i -G, alkyl. In certain embodiments, R ³ is unsubstituted G-G alkyl. In certain embodiments, R ³ is unsubstituted Ci-C ₄ alkyl. In certain embodiments, R ² is unsubstituted C ₁ -C ₃ alkyl. In certain embodiments, R ³ is unsubstituted C ₁ -C ₂ alkyl. In certain embodiments, R ³ is methyl. In certain

embodiments, R ³ is ethyl. In certain embodiments, R ³ is propyl. In certain embodiments, R ³ is butyl. In certain embodiments, R ³ is pentyl. In certain embodiments, R ³ is hexyl. In certain embodiments, R ³ is a nitrogen protecting group. In certain embodiments, R ³ is hydrogen.

[00102] In certain embodiments, R ¹ is substituted or unsubstituted G-G alkylene; R ² is substituted or unsubstituted phenylene; and X is O. In certain embodiments, R ¹ is unsubstituted G-G alkylene; R ² is unsubstituted phenylene; X is O; and R’ is hydrogen.

[00103] In certain embodiments, R ¹ is substituted or unsubstituted G-G alkylene; R ² is substituted or unsubstituted phenylene; and X is S. In certain embodiments, R ¹ is

unsubstituted G-G, alkylene; R ² is unsubstituted phenylene; X is S; and R ³ is hydrogen.

Group R ⁴

[00104] As generally defined herein, R ⁴ is substituted or unsubstituted G-G

heteroaliphatic, substituted or unsubstituted C2-G alkylene, substituted or unsubstituted C ₂ - G alkenylene, or substituted or unsubstituted C2-G alkynylene. In certain embodiments, R ⁴ is substituted or unsubstituted C2-G heteroaliphatic, substituted or unsubstituted C ₂ -G alkylene, or substituted or unsubstituted G-G, alkenylene. In certain embodiments, R ⁴ is unsubstituted C2-C6 heteroaliphatic, unsubstituted C2-C6 alkylene, or unsubstituted C2-C6 alkenylene. In certain embodiments, R ⁴ is unsubstituted C ₂ -C _f , heteroalkylene, unsubstituted C2-C6 alkylene, or unsubstituted C2-C6 alkenylene.

[00105] In certain embodiments, R ⁴ is unsubstituted C2-C6 alkylene. In certain

embodiments, R ⁴ is unsubstituted C2-C5 alkylene. In certain embodiments, R ⁴ is unsubstituted C2-C4 alkylene. In certain embodiments, R ⁴ is unsubstituted C2-C3 alkylene. In certain embodiments, R ⁴ is unsubstituted ethylene.

[00106] In certain embodiments, R ⁴ is unsubstituted C ₂ -Ce alkenylene. In certain embodiments, R ⁴ is unsubstituted C ₂ -C ₅ alkenylene. In certain embodiments, R ⁴ is unsubstituted C ₂ -C ₄ alkenylene. In certain embodiments, R ⁴ is unsubstituted C ₂ -C ₃ alkenylene. In certain embodiments, R ⁴ is unsubstituted ethenylene.

[00107] In certain embodiments, R ⁴ is substituted or unsubstituted C2-C6 heteroalkylene. In certain embodiments, R ⁴ is unsubstituted C2-C6 heteroalkylene. In certain embodiments, R ⁴ is unsubstituted C ₂ -C ₅ heteroalkylene. In certain embodiments, R ⁴ is unsubstituted C ₂ -C ₄ heteroalkylene. In certain embodiments, R ⁴ is unsubstituted C ₂ -C ₃ heteroalkylene. In certain embodiments, R ⁴ is unsubstituted C heteroalkylene. In certain embodiments, R ⁴ is of the formula , wherein Q is O, NR ²⁰ , S, S(O), or S(0) ₂ , and R ²⁰ is hydrogen or Ci-Ce

alkyl. In certain embodiments, R ⁴ is H

[00108] In certain embodiments,

Groups R ⁵ -R ^S

[00109] As generally defined herein, R ⁵ , R ⁶ , R ⁷ , and R ⁸ are each independently hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -N(R ^A )2, or -OR ^A .

[00110] In certain embodiments, R ⁵ , R ⁶ , R ⁷ , and R ⁸ are independently hydrogen, halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl, -N(R ^A ) ₂ , or -OR ^A . In certain embodiments, R ^' , R ⁶ , R ⁷ , and R ⁸ are independently hydrogen, halogen, nitro, cyano, unsubstituted alkyl, unsubstituted alkenyl, -N(R ^A )2, or -OR ^A . In certain embodiments, R ⁵ ,R ⁶ , R', and R ^s are independently hydrogen, halogen, nitro, cyano, unsubstituted Ci-Ce alkyl, unsubstituted C2-C4 alkenyl, -N(R ^A )2, or -OR ^A

[00111] In certain embodiments, R ³ , R ⁶ , R ⁷ , and R ⁸ are independently hydrogen, -N(R ^A ) ₂ , or -OR ^A In certain embodiments, R ⁵ , R ⁶ , R ⁷ , and R ⁸ are independently hydrogen, -N(R ^A ) _2, or -OR ^a ; and each R ^A is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, a nitrogen protecting group, or an oxygen protecting group. In certain embodiments, R ⁵ , R ⁶ , R ⁷ , and R ⁸ are independently hydrogen, -N(R ^A ) ₂ , or -OR ^A ; and each R ^A is independently hydrogen, substituted or unsubstituted acyl, a nitrogen protecting group, or an oxygen protecting group. In certain embodiments, R ⁵ , R ⁶ , R ⁷ , and R ⁸ are independently hydrogen, -N(R ^A ) ₂ , or -OR ^A ; and each R ^A is independently hydrogen, a nitrogen protecting group, or an oxygen protecting group. In certain embodiments, R ³ , R ⁶ , R ', and R ⁸ are independently hydrogen, -N(R ^A ) ₂ , or -OR ^A ; and each R ^A is hydrogen. In certain

embodiments, R ⁵ , R ⁶ , R ⁷ , and R ⁸ are independently hydrogen or -OR ⁴ ; and R ⁴ is hydrogen.

[00112] In certain embodiments, at least one of R ⁵ , R ⁶ , R ⁷ , and R ⁸ is -OR ^A . In certain embodiments, at least one of R ³ , R ⁶ , R ', and R ⁸ is -OH. In certain embodiments, two of R ³ ,

R ⁶ , R ⁷ , and R ⁸ are -OR ^A . In certain embodiments, two of R ⁵ , R ⁶ , R ⁷ , and R ⁸ are -OH. In certain embodiments, R ⁵ and R ⁸ are hydrogen; and R ⁶ and R ⁷ are independently hydrogen or - OR ^a . In certain embodiments, R ³ , R ⁷ , and R ⁸ are each hydrogen. In certain embodiments, R ³ , R ⁷ , and R ⁸ are each hydrogen; and R ⁶ is hydrogen or -OR ^A . In certain embodiments, R ³ , R ⁷ , and R ⁸ are each hydrogen; and R ⁶ is hydrogen or -OH. In certain embodiments, R ⁵ , R ⁶ , R ⁷ , and R ⁸ are each hydrogen.

Embodiments of Formula (I)

[00113] In certain embodiments, the compound of Formula (I) is a compound of Formula (I-a):

(I-a) or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ¹ , R ² , R ³ , X, R ⁴ , R _\ R ⁶ , R', R ⁸ , and R ^A are as defined herein.

[00114] In certain embodiments, the compound of Formula (I) is a compound of Formula

(I-b):

(I-b)

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ¹ , R ² , R ³ , X, R ⁴ , R _\ R ⁶ , R', R ⁸ , and R ^A are as defined herein.

[00115] In certain embodiments, the compound of Formula (I) is a compound of Formula

(I-c):

(I-c)

or a salt, co-ciystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ³ , X, R ⁴ , R ⁵ , R ⁶ , R ⁷ , R ⁸ , and R ⁴ are as defined herein.

[00116] In certain embodiments, the compound of Formula (I) is a compound of Formula

(I-d):

(I-d) or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ⁴ , R ⁵ , R ⁶ , R ', R ^s , and R ^A are as defined herein.

[00117] In certain embodiments, the compound of Formula (I) is a compound of Formula (I-e):

(I-e)

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ⁵ , R ⁶ , R ⁷ , R ⁸ , and R ^A are as defined herein.

[00118] In certain embodiments, the compound of Formula (I) is a compound of Formula

(I-f):

(I-f)

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ⁶ and R ^A are as defined herein.

[00119] In certain embodiments, the compound of Formula (I) is a compound of Formula (I-g):

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ¹ , R ² , and R ³ are as defined herein.

[00120] In certain embodiments, the compound of Formula (I) is a compound of Formula

(I-h):

(I-h)

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ⁵ , R ⁶ , R ⁷ , R ^s , and R ^A are as defined herein.

[00121] In certain embodiments, the compound of Formula (I) is a compound of Formula

(I-i):

(I-i)

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ⁶ and R ^A are as defined herein.

[00122] In certain embodiments, the compound of Formula (I) is a compound of Formula

(I-j):

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ¹ , R ² , and R ³ are as defined herein. [00123] In certain embodiments, the compound of Formula (I) is a compound of Formula (I-k):

(I-k)

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ⁴ , R ⁵ , R ⁶ , R ⁷ , R ⁸ , and R ^A are as defined herein.

[00124] In certain embodiments, the compound of Formula (I) is a compound of Formula

(I-I):

(1-1)

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ³ , R ⁶ , R ⁷ , R ⁸ , and R ^A are as defined herein.

[00125] In certain embodiments, the compound of Formula (I) is a compound of Formula

(I-m):

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ⁶ and R ^A are as defined herein. [00126] In certain embodiments, the compound of Formula (I) is a compound of Formula

(I-n):

(I-n)

or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof, wherein R ¹ , R ² , and R are as defined herein.

[00127] In certain embodiments, the compound of Formula I is a compound of Table 1 , or a salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopically enriched derivative, or chelate complex thereof.

Table 1.

Salts

[00128] In another aspect, disclosed are salts of the compound of Formula (I). In certain embodiments, the salt comprises a metal counterion. In certain embodiments, the metal counterion is bismuth lead, yttrium cadmium, mercury, actinium, thorium, strontium, or a lanthanide. In certain embodiments, the metal counterion has an oxidation state of +3. In certain embodiments, the metal counterion is yttrium, praseodymium, or iutetium. In certain embodiments, the metal counterion is yttrium. In certain embodiments, the metal counterion is Y ³⁺ . In certain embodiments, the metal counterion is praseodymium. In certain

embodiments, the metal counterion is P .

Chelate Complex

[00129] In another aspect, disclosed are chelate complexes comprising the compound of Formula (I) or a salt thereof. A chelate complex is a chemical compound composed of a metal ion and a chelating agent. A chelating agent forms one or more bonds to a single metal ion. In the present disclosure, the compound of Formula (I) may be a chelating agent. In certain embodiments, the chelate complex comprising a compound of Formula (I), or a salt thereof, is a monovalent chelate complex. In certain embodiments, the chelate complex comprising a compound of Formula (I), or a salt thereof, is a divalent chelate complex. In certain embodiments, the chelate complex comprising a compound of Formula (I), or a salt thereof, is a trivaient chelate complex.

[00130] In certain embodiments, the metal ion is bismuth, lead, yttrium, cadmium, mercury, actinium, thorium, strontium, or a lanthanide. In certain embodiments, the metal ion is yttrium, praseodymium, or Iutetium. In certain embodiments, the metal ion has an oxidation state of ÷3. In certain embodiments, the metal ion is yttrium. In certain

embodiments, the metal ion is Y ^{; :} . hi certain embodiments, the metal ion is praseodymium.

In certain embodiments, the metal ion is P’ .

[00131] In certain embodiments, the chelate complex comprising the compound of Formula (I), or a salt thereof, is any of the formula of Table 2.

Table 2.

Kits

[00132] Also encompassed by the disclosure are kits. The kits provided may comprise a compound, salt, or chelate complex described herein and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container). In certain

embodiments, the kit further comprises an activating enzyme. In certain embodiments, the enzyme is a peroxidase. In certain embodiments, the enzyme is horseradish peroxidase.

[00133] Thus, in one aspect, provided are kits including a container comprising a compound, salt, or chelate complex described herein. In certain embodiments, the kits are useful for assaying methods to detect an analyte (e.g., a protein from human tissue, nucleic acids). In certain embodiments, a kit described herein further includes instructions for using the kit.

Methods of use

[00134] Provided herein are DOTA-containing compounds (e.g., compounds of Formula (I)) and complexes that are reactive with an enzyme activator (e.g., a peroxidase) and covalently bind a target analyte (e.g., a protein, nucleic acids) in a catalyzed reporter deposition assaying method. The macrocyclic DOTA portion of the molecule may then act as a reporter group which can be detected directly (e.g., mass spectrometry based imaging) or indirectly (e.g., DOTA antibody coupled to chromogenic deposition of a light-emitting compound and visualization with light or fluorescence microscopy). The compounds are most useful in the methods and uses described herein when they comprise a chelate complex having a metal counterion (e.g., lanthanides, yttrium, praesodynium). The DOTA-containing compounds and complexes are advantageous over existing reporter compounds and complexes because the DOTA moiety allows detection of the reporter moiety by use of mass spectrometry imaging microscopy.

[00135] In one aspect, disclosed is a method of detecting an analyte, the method comprising: reacting an enzyme with a chelate complex (e.g., comprising a compound of Formula (I)) described herein to form an oxidized chelate complex; contacting the oxidized chelate complex with a biological sample; and detecting the analyte in the biological sample.

[00136] In certain embodiments, the method further comprises covalent binding of the oxidized chelate complex with the analyte.

[00137] In certain embodiments, the biological sample is immobilized.

[00138] In certain embodiments, the analyte comprises a protein derived from human tissue.

[00139] In certain embodiments, the enzyme is a peroxidase. In certain embodiments, the enzyme is horseradish peroxidase. In certain embodiments, the analyte does not react with the enzyme.

[00140] In certain embodiments, the detecting of the analyte is direct or indirect. In certain embodiments, the detecting of the analyte is indirect. In certain embodiments, the detecting of the analyte comprises adding a DOTA chelate-specific antibody coupled to chromogenic deposition of a light-emitting compound (e.g., 3.3'-diaminobenzidine tetrahydrochloride) and visualization with light or fluorescence microscopy.

[00141] In certain embodiments, the detecting of the analyte is direct. In certain

embodiments, the detecting of the analyte comprises mass spectrometry^ imaging based microscopy. In certain embodiments, the detecting is achieved by employing mass spectrometry imaging based microscopy. In certain embodiments, the detecting is achieved by employing multiplexed ion beam imaging (MIBI). In certain embodiments, the detecting is achieved by employing Imaging Mass Cytometry™ (IMC™).

EXAMPLES

[00142] In order that the invention described herein may be more fully understood, the following examples are set forth. The examples described in this application are offered to illustrate the compounds, pharmaceutical compositions, and methods provided herein and are not to be construed in any way as limiting their scope. [00143] Compounds of Formula I may be prepared using the synthetic schemes described below.

Preparation of Exemplar y Compounds

[00144] Compound 1 was prepared by the following synthetic scheme.

[00145] Compound 2 was prepared by the following synthetic scheme.

[00146] Compound 3 was prepared by the following synthetic scheme.

[00147] Metal loading of the exemplary' compounds w as accomplished by the following scheme.

M = metal ion

Assays

[00148] Assays were performed to demonstrate the ability of chelate complexes of the exemplary compounds to function in a catalyzed reporter deposition assaying method.

[00149] Tables A-F below describe the stepwise procedure of the assays.

[00150] Table A (anti-nestin positive control) provides the assay procedure for demonstrating the expression of the intermediate filament protein nestin detected in normal human kidney podocytes using a goat anti-nestin polyclonal antibody with a rabbit anti-goat secondary horseradish peroxidase/ 3,3'-diaminobenzidine (DAB) chromogenic assay and standard light microscopy (Figure 1 A).

[00151] Tables B and C provide the assay procedures for demonstrating that the chromogenic signal for nestin expression is not seen with negative control conditions including without anti-nestin primary antibody (Table C; Figure 1C) or without secondary antibody (Table B; Figure IB).

[00152] Table D provides the assay procedure for demonstrating that the nestin-specific signal is not seen without the DOTA chelate complex in the anti-DOTA antibody assay (Figure ID).

[00153] Table E provides the assay procedure for evaluating exemplary compounds 1, 2, and 3 having DOTA complexed to Pr’ (Figure IE, Figure II, Figure 1M) or Y ³⁺ (Figure IF, Figure 1J, Figure IN) or not complexed (Figure 1G, Figure IK, Figure 10). In each assay the complex was oxidized by peroxidase and deposited at the site of the anti-nestin antibody.

This specific deposition of complex was detected with an anti-DOTA chelate antibody (clone 2D12.5) chromogenic assay using DAB. Empty DOTA is not recognized by the anti-DOTA chelate antibody (clone 2DI2.5), therefore chromogenic signal was not seen in these assay conditions (Figure 1G, Figure IK, Figure 10). [00154] Table F provides the assay procedure for evaluating exemplary compounds 1, 2, and 3 having DOTA complexed to Y ³ (Figure 1H, Figure 1L, Figure IP) but without addition of the anti-DOTA antibody to the assay. Nestin-specific signal was not seen without anti-DOTA chelate antibody (Figure 1H, Figure 1 L, Figure IP).

[00155] Figure 2 confirms that the disclosed compounds can be detected by a mass spectrometry imaging device in an assay. Images were generated using a MIBIscope I multiplexed ion beam imaging device from IONpath (Menlo Park, CA). The parenthetical terms 1 :4K, 1 :2K, and 1 : IK refer to the dilution of the compound used in the assay. In particular, compounds 1 and 3 complexed to Pr (Figures 2A, 2C) or Y ³⁺ (Figures 2B, 2D) were detected directly in human placenta samples using the mass spectrometry imaging device.

Table A

Step Reagent Supplier Santa Cni e

Cat# SC-21248;

Lot# A2 13

Dispei se type. 150 mΐ.

Step type: Reagent

Inc. (min): 30:00 Temperature: Ambient

Step Reagent Supplier: Leica Microsystem

2 * BondWashSoliilkm

Step ! ptv. Wash In·:;, (min): 0.00 MTip raluie: Ambi nt Dsapens·.: ; vf;·.:. 150 f: i .

Step Reagent Supplier: Leica Microsystems

3 *Bond ashSo]ution

Step type: Wash Inc. (imn): 0:00 nnperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

4 *B o ad WashSoi u t ion

Step Reagent Supplier: Leica Microsystems

5 * BondWashSoliilkm

Step type: Wash Trie, (min): 2.00 eriperatiire: Ambient Dispense type. 150 pi.

Step Reagent Supplier: Leica Microsystems

6 *BondWashSoiution

Step Reagent Supplier: Leica Microsystems

7 *BondWashSolution

Step type: Wash Ine (min): 2:00 Temperature: Ambient Dispens type: :50 m

Step Reagent Supplier: Vector Lab

Cat# BA-5000

Stic, (min): 8:00 emperatiive: Ambient Dispense type: ! 50 C Table A (continued)

Step Reagent Supplier: Leica Microsystems

9 *B o nd WashSoi u t ion

Step type: Wash Inc. (rain): 2:00 Temperature: Ambient Dispense type: iS pL

Step Reagent Supplier: Leica Microsystems

10 ^BondWashScdution

Step type: Wash Trie, (min): 2.00 Tempera lure: Ambient Dispense type. 150 mΐ.

Step Reagent Supplier: Leica Microsystems

11 *BondWashSolution

Step type: Wash Inc. timn ): 2:00 Temperature: Ambient Dispense type: ? 50 pL

Step Reagent Supplier: Leica Microsystems 12 *Poiymer

Step type: Reagent Inc. (min): 8:00 Temperature : A mbien t Dispense type: ISO mT

Step Reagent Supplier: Leica Microsystems

13 ^BondWashScdution

Step type: Wash Inc. (mini: 2:00 I emperature: Ambient Dispense type: 150 pL

Step Reagent Sit pp li er: Le tea M

14 ^! Bon WashSolution

Step type: Wash Inc (min): TOO Temperature: Ambient Dispense type· ! SO pL

Step Reagent Supplier: Leica Microsystems

15 * BondWashSoluiion

Step type: Wash Inc. (min): 2:00 Temperature : Am bi eni Dispense type: 150 mT

Step Reagent Supplier: Leica Microsystems

16 *BondWashSohftion

Step type: Wash Inc. ftmn ): 0:00 Temperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

17 ^>; ‘Peroxide Block

Step type: Reagent Inc. {ini n): 5:00 p ramrc: Ambient Di pense type: i50 pL

Step Reagent Supplier: Leica Microsystems

18 ^BondWashScdution

Step Reagent Su pp ii er: Le ica Mi cm sy tems

19 *BondWashSolutio«

Step Reagent Supplier: Leica Microsystems

20 *BondWashSolution

Step type: Wash Trie, (min): 0.00 eri ralui : Ambient Dispense type. 150 pi.

Step Reagent Supplier: Notappiicable

21 *Deionized Water

Step type: Reagent Inc. (mini: 0:00 e mperat ure : Ambient Dispense type: 50 pi

Step Reagent Supplier: Notappiicable

05 *Deionized Water

Step type: Wash Inc. (min): 0:00 inpetntnre : A bient Dispense type- · 50 mί-

Step Reagent Supplier: Leica Microsystems

23 *Mixed DABEe fine

Step type: Reagent Trie, (min): 2.00 eriperaleie Ambient Dispense type. 150 pi.

Step Reagent Supplier: Leica Microsystems

24 *Mixed D ABRefine

Step type: Reagent Inc. imiii >; 5:00 Temperature. Ambient Dispense type: 1 0 mΐ.

Step Reagent Supplier: Nolappllcab!e

2.5 ^Deionized Water

Step type: Wash Inc. (min): 0:00 Temperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Notapplkable

26 "Deionized Water

Step type: Wash Inc. (min): 0:00 Temperature: Ambient Dispense type: 150 pi.

Step til Supplier; Notappiicable

27 "Deionized Water

Step type: Wash Inc. (min): 0 00 Temperature .Ambient Dispense type I όO mT-

Step Reagent Supplier: Leica Microsystems

28 ^Hematoxylin

Step type: Reagent In·:;, (min): 10:00 empeeatur e: Ambieri t Dispense type. 150 pi.

Step Reagent Supplier: Notapphcable

29’"Deionized Water

Step type: Wash Inc. (mini: 0:00 Teraperature:Ambieat Dispense type: 150 pi

Step Reagent Supplier: Leica Microsystems

30 *BondWashSolution

Step type: Wash Inc (min): 1 ·00 Temperature: Ambient Dispense type· ! SO pL

Step Reagent Supplier: Leica Microsystems

31 *Bond WashSolution

Step type: Wash Inc. (miu): 0.00 Temperature: Ambient Dispense type. 150 pi.

Step Reagent Supplier : Notapphcable

32 "Deionized Water

Step type: Wash inc. (min i: 0:0 Temperature: Ambient Dispense type: ! 50 pL Step Reagent Supplier: Santa Cruze

Cat# SC-21248;

Step Reagent Supplier: Leica Microsystems

2 * BondWashSolutioii

Step type: Wash ine. (min): 0:00 t emperature : Am · i eni Di ens type: 150 mΐ

Step Reagent Supplier: Leica Microsystems

3 *BondWashSoiution

Step Reagent Supplier: Leica Microsystems

4 *B o nd WashSoi u t ion

Step type: Wash Ine. OninV 0:00 emperalure: Ambient Dispense type: : 50 pL

Ste Reagent Su pp ii er: Le ica M i cm systems

6 Boh<3 W as h S o I ut i cm

Step Reagent Supplier: Leica Microsystems

T *BondWashSolution

Step type: Wash ine. (r an): 2:00 t emperature : Am Pi eni Dispense type: 150 m :

Step Reagent Supplier:

8 TBS-t

Step type: Reagent Inc. (min): S :00 remperalure: Ambient Dispense type: ! 50 mI Table B (continued)

Step Reagent. Supplier: Le.ica Microsystems

9 *B o n WashSoi u t ion

Step type: Wash Inc (min): 2:00 Temperature: Ambient Dispense type ! 50 j.tL

Step Reagent Supplier: Leica Microsystems

10 ^BondWashScdution

Step type. Wash Trie, (min): 2.00 Temperature: Ambient Dispense type. 150 pi.

Step Reagent Supplier: Leica Microsystems

11 *BondWashSoiution

Step type: Wash inc. (mi i: 2:00 Temperature. Ambient Dispense type: 150 mT

Step Reagent Supplier: Leica Microsystems

12 *Po!ymer

Step type: Reagent Inc. (min): 8:00 Temperature: Ambient Dispense type: iSO pL

Step Reagent Supplier: Leica Microsystems

13 *BondWashSoliition

Step type: Wash Ine. (min): 2:00 Temperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

14 ''Bond WashSolution

Step type: Wash Inc (min): 2:00 empeiature: Ambient Dispense type· ! 50 _j.t L

Step Reagent Supplier: Leica Microsystems

15 * BondWashSoluiioii

Step type: Wash ine. (min): 2:00 ^' ernperamre: Ambient Dispense type: ISO mT

Step Reagent Supplier: Leica Microsystems

16 *BondWashSo!utiot

Step type: Wash inc. Omn i: 0:00 Temperature: Ambie Dispense type: ] 50 mϊ

Step Reagent Supplier: Leica Microsystems 17 ^Peroxide Block

Step type: Reagent Inc. (min): 5:00 temperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

18 *B o nd Was h S o 1 u t ion

Step Reagent Supplier: Leica Microsystems

1 * Bon W ashSohuion

Step type: Wash Trie, (min): 0.00 imperature: Ambient Dispense type. Open

Step Reagent Supplier: Leica Microsystems

20 *BondWashSoiution

Step type: Wash Inc . i mm i: 0:00 Temperature: Ambie Dispense type: ] 50 mϊ

Step Reagent Supplier: Notapplicable

21 ^Deionized Water

Step type: Reagent Inc. (min): 0:00 emper autre : Ambient Dispense type: :5 m

Step Reagent Supplier: Notapplicable

22 "Deionized Water

Step type: Wash Inc. (min): 0:00 erriperatf ie: Ambient Dispense type: 150 pi.

Step Reage»! Su pp ii er: Le tea Mi cm systems

23 -"Mixed DAB Refine

Step Reagent Supplier: Leica Microsystems

24 Mixed D ABRefine

Step type: Reagent Trie, (min): 5.00 imperature: Ambient Dispense type. Ϊ50 pi.

25 «Deionized Water

Step type: Wash Inc. (min): 0:00 cmpcrature: Ambient Dispense type: i 50 m!

Step Reagent Sapp! ie r: Notappl icab l e

26 ' Deionized Water

Step type: Wash Ine. (min): 0:00 etnperalnre : A mbient Dispense type· ! 50 pL

Step Reagent Supplier: Notapplicahle

27 «Deionized Water

Step type: Wash Stic, (min): 0:00 emperatuf e: Ambient Dispense type. 150 pi.

Step Reagent Supplier: Leica Microsystems

28 «Hematoxylin

Step type: Reagent Inc. i min i: 10:00 Temperature: Ambient Dispense type: 150 mϊ

Step Reagent Sapp! ie r: Notappl icab ! e

29 «Deionized Water

Step type: Wash Inc. (min): 0:00 Temperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

30 «BondWashScdution

Step type: Wash Ine. (min): 1:00 Temperatute· Ambient Dispense type: 150 pi.

Step Reagent S pp ii er: Le tea Mi cm systems

31 ^' «Bond Was h S o i ut i on

Step type: Wash ine. (min i: 0:00 Temperature. Ambient Dispense type: 150 pL

Step Reagent Supplier: Notapplicahle

32 «Deionized Water

Step type: Wash. Stic, (min): 0:00 Temperature: Ambient Dispense type. 150 pi.

Step Reagent Supplier: Leica Microsystems

2 *BondWashSolution

Step type: Wash ine. (man): 0:00 f ernperature : Am Pi er· t Dispense type: 150 mΐ

Step Reagent Supplier: Leica Microsystems

3 *Bond ashSo]iition

Step type: Wash Ine. (mil i): 0:00 nnperatu re: Ambient Dispense type: 50 pL

Step Reagent Supplier: Leica Microsystems

4 *B o nd WashSof u t ion

Step Reagent Supplier: Leica Microsystems

5 * BondWashSolutioii

Step type: Wash Inc. («jin); 2.00 nnperafme Ambient Dispense type. 150 pi.

Step Reagent Supplier: Leica Microsystems

6 *BondWashSoiution

Step Reagent Supplier: Leica Microsystems

7 *BondWashSolution

Step type: Wash Inc. (min): 2:00 t ernperature : Am t)i eni Dispense type: ISO mύ

Step Reagent Supplier: Vector Lab

Cat# BA-5000

8 Rabbit anti- goaf igG

Stic, (min): 8:00 rempetaUire.' Ambient Dispense type: ! SO pL

Step type: Reagent Table C (continued)

Step Reagent. Supplier: Le.ica Microsystems

9 *B o nd WashSoi u t ion

Step type: Wash Inc (min): 2:00 Temperature: Ambient Dispense type ! 50 j.tL

Step Reagent Supplier: Leica Microsystems

10 ^BondWashScdution

Step type. Wash Trie, (min): 2.00 Tssmpssrature: Ambient Dispense type. i ₅ 0 pi.

Step Reagent Supplier: Leica Microsystems

11 *BondWashSoiution

Step type: Wash inc. (mi i: 2:00 Temperature. Ambient Dispense type: 150 mT

Step Reagent Supplier: Leica Microsystems

12 *Polymer

Step type: Reagent Inc. (min): 8:00 Temperature: Ambient Dispense type: 150 pi

Step Reagent Supplier: Leica Microsystems

13 *BondWashSoliition

Step type: Wash Inc. (min): 2:00 Temperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

14 ^!t Bon WashSolution

Step type: Wash inc (min): 2:00 Temperature: Ambient Dispense type· ! 50 _j.t L

Step Reagent Supplier: Leica Microsystems

15 * BondWashSoluiion

Step type: Wash inc. (min): 2:00 Temperature: Ambient Dispense type: 150 pi

Step Reagent Supplier: Leica Microsystems

16 *BondWashSo!ution

Step type: Wash Inc. ( min i: 0:00 Temperature: Ambient Dispense type: I SO pL

Step Reagent Supplier: Leica Microsystems

17 ^>; ‘Peroxide Block

Step type: Reagent Inc. {ini n): 5:00 p ramrc: Ambient Di pense type: i50 pL

Step Reagent Supplier: Leica Microsystems

18 ^BondWashScdution

Step Reagent Su pp ii er: Le ica Mi cm sy tems

19 *BondWashSolutio«

Step Reagent Supplier: Leica Microsystems

20 *BondWashSolution

Step type: Wash Trie, (min): 0.00 eri ralui : Ambient Dispense type. 150 pi.

Step Reagent Supplier: Notappiicable

21 *Deionized Water

Step type: Reagent Inc. (mini: 0:00 e mperat ure : Ambient Dispense type: 50 pi

Step Reagent Supplier: Notappiicable

05 *Deionized Water

Step type: Wash Inc. (min): 0:00 inpetntnre : A bient Dispense type- · 50 mί-

Step Reagent Supplier: Leica Microsystems

23 *Mixed DABEe fine

Step type: Reagent Trie, (min): 2.00 eriperaleie Ambient Dispense type. 150 pi.

Step Reagent Supplier: Leica Microsystems

24 *Mixed D ABRefine

Step type: Reagent Inc. imiii >; 5:00 Temperature. Ambient Dispense type: 1 0 mΐ.

Step Reagent Supplier: Nolappllcab!e

2.5 ^Deionized Water

Step type: Wash Inc. (min): 0:00 Temperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Notapplkable

26 "Deionized Water

Step type: Wash Inc. (min): 0:00 Temperature: Ambient Dispense type: 150 pi.

Step til Supplier; Notappiicable

27 "Deionized Water

Step type: Wash Inc. (min): 0 00 Temperature .Ambient Dispense type I όO mT-

Step Reagent Supplier: Leica Microsystems

28 ^Hematoxylin

Step type: Reagent In·:;, (min): 10:00 empeeatur e: Ambieri t Dispense type. 150 pi.

Step Reagent Supplier: Notapphcable

29’"Deionized Water

Step type: Wash Inc. (mini: 0:00 Teraperature:Ambieat Dispense type: 150 pi

Step Reagent Supplier: Leica Microsystems

30 *BondWashSolution

Step type: Wash Inc (min): 1 ·00 Temperature: Ambient Dispense type· ! SO pL

Step Reagent Supplier: Leica Microsystems

31 *Bond WashSolution

Step type: Wash Inc. (miu): 0.00 Temperature: Ambient Dispense type. 150 pi.

Step Reagent Supplier : Notapphcable

32 "Deionized Water

Step type: Wash inc. (min i: 0:0 Temperature: Ambient Dispense type: ! 50 pL Step Reagent Supplier: SantaCmze, (Cat# SC-2!248;

Lot# A2313)

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

2 *BondWashSolution

Step type: Wash Inc. (min): 2:00 e perature: Ambient Dispense type: 150 pi.

Step Reagent Supplier: L

3 «BondWashSolutiori

4 ^' «Bond Was h S ol ut i on

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

5 * BondWashSoluiion

Step type: Wash Inc. (min): 0:00 iemperamre : Am Pi er Dispense type: 150 pL

Step Reagent Supplier: Vector Lab (Cat# BA-5000}

6 Rabbit anii- goat

secondary Inc. (mini: 8:00 emperature: Ambient Dispense type: 150 pi antibody

Step type: Reagent

Step Reagent Supplier: Leica Microsystems Table D (continued)

Step Reagent Supplier: Leica Microsystems

Cat # AR9590

8 *BondWashSo!ution

Step type: Wash Inc. (min): 2:00 temperature: Ambient Dispense type: !S pL

Step Reagent Supplier: Leica Microsystems

9 *B o nd WashSoi u t ion Cal# AR9590

Step type: Wash Inc. (rain): 2:00 Temperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

10 ^BondWashSolution

Step type: Wash Inc. (min): 0:00 Temperatute· Ambient Dispense type: 150 yL

Step Reagent Supplier: Bond Polymer Refine Detection kit

12 ^s Bond Wash Solution

Step type: Wash Inc. (min i: 2:00 Temperature. Ambient Dispense type: ISO mΐ

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

13 *BondWashSolution

Step type: Wash Inc. (man): 2:00 Temperature: Am _b ient Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

14 *BondWashSolution

Step type: Wash Inc. (min): 2:00 Temperature: Ambient Dispense type: IsO pL

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

15 *BondWashSolution

Step type: Wash Inc (min): <>00 Temperature: Ambient Dispense type: 150 mΐ.

16 TBS-t

Step type: Reagent Inc (min): i0:00 Tcinperatnm: Ambient Dispense type: 150 pi.

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

17 ^BondWashSolution

Step type: Wash Tri , (min): 2.00 temperature: Ambient Dispense type: 150 mϊ-

Step Reagent Supplier:

18 *B o nd Was h S o 1 u t ion

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

1 * Bon W ashSohuion

Step type: Wash Inc. (min): 2:00 emperalure: Ambient Dispense ij'pe: 150 pL

Step Reagent Supplier:

20 *BondWashSo!ution

Step Reagent Supplier: Perkin Elmer 21 AR9 Buffer Cat#AR900250ML

Step type: Reagent Inc. (min i: 0:00 Temperature: : 00'

Dispense type· 150 pL

Step Reagent Supplier: Perkin Elmer

Cai#AR900250M .

22 AR9 Buffer

Step type: Reagent Trie, (min): 20:00 Temperature; 100 ^" C Dispense type: ! 50 mί

Step Reagent Supplie

23 AR9 Buffer

Step type: Reagent inc. i min i: 0:00 Temperature: 100 Dispense type: !50 j-iL Table D (continued)

Step Reagent Supplier: Perkin Elmer

Cai#AR900250ML

24 AR9 Buffer

Step type: Reagent Inc (min): 2:00 Temperature: Ambient Dispense ty e 150 pi.

Step Reagent Supplier: Perkin Rimer

Cat#AR900250ML

25 AR9 Buffer

Step type: Reagent i n·::. (natn): 0.00 Temperature: Ambient Dispense type: 150 r : .

Step Reagent Supplier:

26 *BondWashSoiutio«

Step type: Wash Inc. ⁽ rain .i: 0:00 Tempemtnve. Ambient Dispense type: 150 pL

Step Reagent Supplier: Vector Lab

CV«#MP-7402 kit

27 Normal horse serum

Step type: Reagent Inc. (min): 10:00 Temperature: Ambient Dispense type: 150 pL

Step Reagent Supplier

Step type: Reagent

Step Reagent Supplier:

29 *BondWashSo!utiot

Step type: Wash Inc. (min): 2:00 Temperature· Ambient Dispense type: 150 r : .

Step Reagent Supplier:

30 *BondWashSolutio«

Step type: Wash Inc. <mui ): 2:00 Temperature: Ambient Dispense type: 150 mΐ.

Step Reagent Supplier:

31 * Bon W ashSohuion

Step type: Wash ine. (man): 2:00 Temperature : Am Di ent Dispense type: ! 50 pL

32 *BondWashSolution

Step type: Wash Ine (min): (TOO Temperature: Ambient Dispense type: 150 t.

Step Reagent Supplier: Vector Lab

Cat# MP-7402 kit

33 Horse anli-rnouse

IgG

Trie, (min): 20:00 Temperature: Ambient Dispense type: 150 pD

Step type: Reagent

Step Reagent Supplier: Leica Microsystems

Cat # AR9590

34 *BondWashSolution

Step type: Wash Ine (min): 2Ό0 Temperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

Cat # AR9590

35 *BondWashSohftion

Step type: Wash Inc. (min): 2:00 Temperature· Ambient Dispense type: 350 pT

Step Reagent Su pp ii er:

36 *BondWashSofution

Step type: Wash Ine (min): 2'00 Temperature: Ambient Dispense type: 150 pr

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

37 * Bon W ashSohition

Step type: Wash In·:;, (min): 0.00 Temperature: Ambient Dispense type: 350 pL

Step Reagent Suppli

38 ^Peroxide Block

Step type: Reagent Inc. (min): 8:00 Temperature: Ambient Dispens type: !bO pL

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

39 *BondWashSolution

Step type: Wash Inc. (min): 0:00 T emperalure : Ant bie Dispense type: 150 pL

Step essgent Supplier: Leica Micmsysmm

Cat# AR9590

40 *Bond Wash Solution

Step type: Wash Inc (min).0 00 e penUure: Ambie;; Dispense :ype. Open

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

41 «BondWashSoiution

42 «Deionized Water

tep type: Reagent tne. (min i: 0:00 emperaUire: Ambient Dispense type: ] 50 mϊ-

Step Reagent Supplier: B. BRAUN Medical Inc: BRS000-01

43 «Deionized Water

Step type: Wash Inc. (min): 0:00 emper autre : Ambient Dispense type: :50 pL

Step Reagent Supplier: Bond Polyme Refine Detection kit

44 «Mixed DABRe fine Cat# DS9800

Step type: Reagent Inc. (min): 2:00

emperalure: Ambient Dispense type: 150 m :

Step Reagent Supplier: Bond Polymer Refine Detection kil

45 «Mixed DABRefitse Cat# DS9300

Step type: Reagent Inc. (min): 5:00

emperalure: Ambient Dispense type: 150 pi.

Step Reagent Supplier: B. BRAUN Medical h

46 «Deionized Water

Step type: Wash Inc. (min i: 0:00 emperalure: Ambient Dispense type: ! 50 pL

Step Reagent Supplier: B. BRAUN Medical In

47 «Deionized Water

Step type: Wash Inc. (min): 0:00 emperauire : Ambient Dispense type: i50 pL Table D (continued)

Step Reagent Supplier: 8. BRAUN Medical In

48 'Deionized Water

Step type: Wash Inc. (min): 0:0C lcmpcrature:Ambient Dispense type: 150 pL

Step Reagent Supplier: Bond Polymer Refine Detection kit

Step Reagent Supplier: B. BRAUN Medical inc. HR5000 01

50 ^Deionized Water

Step type: Wash lne. (min): 0:00 T emper autre : Ambient Dispense type: :50 pL

Step Reagent Supplie

51 *Bond WashSoliition

52 *B o nd Was h S o 1 u t ion

Step type: Wash lne. (min y.0:00 Temperature. Ambient ispense type: 150 pi.

Step Reagent Supplier: 8 B

53 ^Deionized Water

Step type: Wash Inc. (min): 0:00 Temperature: Ambient Dispense type: 150 mT

Table E

Step Reagent Supplie a _t # SC-21248;

Step type: Reagent

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

2 * BondWashSolutioii

Step type: Wash Inc (rain): 2:00 emperalure: Ambient Dispense type: 150 pL

Step Reagent Supplier: L

3 *BondWashSoiution

Step type: Wash Inc (min): 2:00 ;mperature: Ambient Dispense type: I SO pL

Step Reagent Supplier: Leica Microsystems

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

5 *BondWashSolution

Step type: Wash Trie, (mitt): 0.00 aTiperatufe: Ambient Dispense type: ] 50 mϊ-

Step Reagent Supplier: Vector Lab (Cat# BA-5000)

Step Reagent Supplier: Leica Microsystems

7 *BondWashSol«tion Cat# AR9590

Step type: Wash Inc. (mm): 2:00 Temperature: Ambis Dispense type: 150 pi.

Step Reagent Supplier: Leica Microsystems

Cat # AR95 0

8 *BondWashSolution

Step type: W ash Inc. (min): 2:00 temperature: Ambient Dispense type: !5 .L

Step Reagent Supplier: Leica Microsystems

Step Reagent Supplier : Leica Microsystems

Cali AR9590

10 *Bond WashSolution

Step type: Wash Inc. (min): 0:00 Temperature· Ambient Dispense type: 150 pL

Step Reagent Supplier: Bond Polymer Refine Detection kit

Step Reagent Supplier: Leica Microsystems

Car# AR9590

12 ^s Bond Wash Solution

Step type: Wash Inc. (min r.2:00 Temperature. Ambient Dispense type: ISO pL

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

13 *BondWashSolution

Step type: Wash ine. (man): 2:00 Temperamre : Am Pi eni Dispense type: 150 pL

Step Reagent Supplier:

14 *BondWashSolution

Step type: Wash Inc. (min): 2:00 1 emperature: Ambient Dispense type: !S pL

Step Reagent Supplier: Leica Microsystems

Cm# AR9590

15 *BondWashSolution

Step type: Wash Lite (min): 0'00 Temperature: Ambient Dispense type: 150 pi. Table E (continued)

Step Reagent Supplier: MSKCC

16 Compound

Step type: Reagent in (min) K ⁾ :00 Temperature: Ambient Dispense ty e· ! SO pL

Step Reagent Supplier: Leica Microsystems

Cat # AR9590

17 *BondWashSolution

Step type: Wash Trie, (min): 2.00 Tcari cratuie: Ambi-an Dispense type: 150 mϊ-

Step Reagent Supplier:

18 *BondWashSolution

Step type: Wash ine. ⁽ min y.2:00 Temperature. Arnbien Dispense type: ISO mΐ

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

19 *BondWashSolution

Step type: Wash ine. (min): 2:00 Temperature : Am Pi eni Dispense type: 150 pL

Step Reagent Supplier:

20 *BondWashSoiution

Step type: Wash Inc. (min): 0:00 jmperature: Ambient Dispense type: I SO pL

Step Reagent Supplier: Perkin Elmer 21 AR9 Buffer Cat#AR900250ML

Step type: Re&geiH Inc. <min >: 0:00 Temperas ure: 100°C

Dispense type· 150 pL

Step Reagent Supplier: Pei kin Elmer

Cat#AR900250Ml.

22 AR9 Buffer

Ste type: R agent Inc. (min); 20.00 Tempe u v. 100 C Dispense type: ! 50 pt

Step Reagent Supplier: Perkin Elmer

Cat#AR900250ML 23 AR9 Buffer

Step type: Reagent Inc. (min): 0:00 Temperature: 100 Dispense type: ISO mΐ Table E (continued)

Step Reagent Supplier: Perkin Elmer

Cat#AR900250M

24 AR9 Buffer

Step type: Reagent ine. i min i: 2:00 Temperature: Ambient

Step Reagent Supplier: Perkin Elmer

Cat#AR900250ML 25 AR9 Buffer

Step type: Reagent ine. (min): 0:00 emperamre: Am _b ient Dispense iypc: 150 pL

Step Reagent Supplie

26 *BondWashSo!utiot

Step type: Wash Inc. (min): 0:00 1 emperature: Ambient Dispense type: ! 50 pL

Step Reagent Supplier: Vector Lab

Cat# MP-7402 kit

27 Normal horse serum

Step type: Reagent ine. tmin i: !0:00

Step Reagent Supplier: Creative Biolabs (2D 12.5)

Cat# PABW-133

Step type: Reagent

Step Reagent Supplier: Leica M icrosysiems

Cat# AR9590

29 * Bon W ashSohuion

Step type: Wash Ine. (min): 2:00 emperamre: Ambient Dispense type: 150 pL

Step Reagent Supplier

30 *BondWashSoiution

Step type: Wash Inc. <ntin>: 2:00 emperatu re: Ambient Dispense type: ! 50 mί-

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

31 *BondWashSolution

Table E (continued)

Step Reagent Supplier: Le.ica Microsystems

Car# AR9590

32 *BondWashSolution

Step Reagent Supplier: Vector Lab

Cat# MP-7402 kit

33 Horse anti-rnouse

IgG Trie. (min): 20:00 arip ralui : Ambient Dispense type: 150 mϊ-

Step type: Reagent

Step Reagent Supplier

34 *BondWashSolutioii

Step Reagent Supplier: Leica Microsystems

Cat # AR9590

35 *BondWashSohftion

36 *BondWashSoiutio«

37 * Bon W ashSohuion

Step type: Wash Trie, (min): 0.00 nyiperateie Ambient Dispense type: ! 50 pL

Step Reagent Supplier: Bon

38 "Pero ide Block

Step type: Reagent Inc. (min): 8:0C jmperature: Ambient Di pense type: 150 m

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

30 *BondWashSolution

Step type: Wash Inc (min): 0:00 emperaiure: Ambient Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

40 *BondWashSoi ution

Step type: Wash Inc. (min): 0:00 1 emperature: Ambient Dispense type: Open

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

41 *BondW ashSolution

Step type: Wash Itte (min): <>00 Temperature: Ambient Dispense type: 150 pi.

Step Reagent Supplier: 8. B

42“Deionized Water

Step type: Reagent Inc. (min): 0:00 Temperature: Ambient Dispense type: 150 pi.

Step Reagent Supplier: B. BRAUN Medic

43 ^‘ “Deionized Water

Step type: Wash Ine. (min i: 0:00 Temperature: Ambient Dispense type: ! 50 mT

Step Reagent Supplier: Bond Polymer Refin Detection kit

44 Mixed D ABRefine Cat# DS9800

Step type: Reagent ine. (min): 2:00

Temperature: Ambient Dispense type: ! 50 _j.t L

Step Reagent Supplier: Bond Polymer Refine Detection kit

45“Mixed DABRe fine Cat# DS 800

Step type: Reagent Inc. (min): 5-00

Temperature. Ambient Dispense type: ! 50 _j.t L

Step Reagent Supplier: 8 BRAUN MedicaUnc. *R5000-OI

46’‘Deionized Water

Step type: Wash Inc. (min): 0:00 Temperatute: Ambient Dispense type: 150 pi.

Step Reagent Supplier: B. BRA UN Medical in

47 ^‘ “Deionized Water

Step type: Wash Ine. (min): 0 00 T emperature : A mbient Dispense type· ! 50 mA

Step Reagent Supplier: B. BRAUN Medical hie. #R5000-Q!

48 *Deionized Water

Step type: Wash Inc. ( in): 0:00 1 emperature: Ambient Dispense type: 150 pL

Step Reagent Supplier: Bond Polymer Refine Detection kil

Step Reagent Supplier: B. BRAUN Medical Inc. PR5000 01

50’-Deionized Water

Step type: Wash ine. (min): 0:00 T emper amre : Ambient Dispense type: 150 pL

Step Reagent Supplie

51 *BondWashSoiution

Step type: Wash Ine. (min): 1 :00 I emperature: Ambient Dispense type: I SO pL

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

52 *BondWashSolution

Step type: Wash Ine (min): 0-00 Temperature: Ambient Dispense type: 150 pi.

Step Reagent Supplier: 8. BRAUN Medical Int. #R5000-01

53 *Deionized Water

Step type: Wash Inc. (min): 0:00 emperature: Ambient Dispense type: ISO pi

Table F

Step Reagent Supplier: SansaCruze, (Cat# SC-21248;

Lot# A2313)

Step type: Reagent

Step Reagent Supplier: L

2 «BondWashSolution

Step type: Wash ine. (min): 2:00 Temperature : Am Pi eni Dispense type: 150 e i .

Step Reagent Supplier: Le

3 ^' «Bond Was h S ol ut i on

Step type: Wash inc. i min i: 2:00 Temperature: Ambient Dispense ty pe: IsO pL

Step Reagent Supplier: Leica Microsystems

Car# AR9590

4 *BondW ashSolution

Step type: Wash Ine. (min): 2:00 Temperature: Ambient Dispense type. 150 e - .

Step Reagent Supplier: Leica Microsystems

Cat# AR95 0

5 «BondWashSolution

Step type: Wash Ine. (min): 0:00 temperature: Ambient Dispense type: ! 50 pL

Step Reagent Supplier: Vector Lab ( Cat# BA-5000)

Step Reagent Su pp ii er: Le ica Mi cm systems

7 «Bond W as h S ol ut i on

Cat# AR9590

Step type: Wash ine. (min i: 2:00 Temperature. Ambient Dispense type: 150 pi. Table F (continued)

Step Reagent Supplier:

S *BondWashSolution

Step type: Wash Inc. (min): 2:00 Temperature: Ambient Dispense type: ! SO pL

Step Reagent Supplier: Leica Microsystems

9 *BondWashSo!ution Cat# AR9590

Step type: Wash Inc. (min): 2:00 1 emperature: Ambient Dispense type: ISO mT

Step Reagent Supplier: Leica Microsystems

Cat # AR9590

10 *BondWashSolution

Step type: Wash Inc. (min): 0:00 Temperature: Ambient Dispense type: 150 pi.

Step Reagent

1 1 ^Polymer Cat# DSVSOO

Step type: Reagent Inc. (min): 8:00 Temperature: Ambient

Dispense type: ! 50 pL

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

12 *Bond ashSoli!tion

Step type: Wash Trie, (mitt): 2.00 Temperature: Ambient Dispense type: 150 u : .

Step Reagent Supplier: L

13 *BondWashSolution

Step type: Wash Inc. (min i: 2:00 Temperature. Ambient Dispense type: 150 mT

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

14 * Bon W ashSohuion

Step type: Wash Inc. (min): 2:00 Temperature : Am Pi eni Dispense type: 150 pL

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

15 *BondWashSolution

Step type: Wash Inc. (min): 0:00 1 emperature: Ambient Dispense type: ! 50 pL

Step Reagent Supplier: MSKCC

16 Compound

Step type: Reagent Inc. (min): 10:00 Temperature: Ambient Dispense type: 150 p.L

Step Reagent Supplie

17 *Bond WashSohtiion

Step type: Wash Inc. (min): 2:00 Temperature· Ambient Dispense type: ! 50 L

Step Reagent Su pp ii er:

18 *BondWashSoiutio«

Step type: Wash Inc (min): 2'00 Temperature: Ambient Dispense type: 150 mΐ.

Step Reagent Supplier:

1 * Bond W ashSohuion

Step type: Wash Trie, (mitt): 2.00 Temperature: Ambient Dispense type: ! 50 pL

Step Reagent Supplier:

20 ^‘« Bond Was h S ol ut i on

Step type: Wash Inc. (t n ): 0:00 Temperature: Ambient Dispense type: !50 .L

Step Reagent Supplier: Perkin Elmer

21 AR9 Buffet- Cat#AR900250ML

Step type: Reagent Inc (min): 0-00 Temperature· 100°C

Dispense type' 150 pL

Step Reagent Supplier: Perkin Elmer

Cat#AR900250ML

22 AR9 Buffer

Step type: Reagent Ine. (min): 20:00 Temperature: IO0 C Dispense type: 150 e : .

Step Reagent Supplier: Perkin Elmer

Cai#AR900250ML 23 AE9 Buffet-

Step type: Reagent Inc. <mtn ): 0:00 Temperature: 100 Dispense type: 150 mΐ. Table F (continued)

Step Reagent Supplier: Perkin Elmer

Car#AR900250ML 24 AR9 Buffer

Step type: Reagent Inc. (min): 2:00 emperalure: Ambient Dispense type: 150 pL

Step Reagent Supplier: Perkin Elmer

Cai#AR900250ML 25 AR9 Buffer

26 *BondWashSolution

Step Reagent Supplier: Vector Lab

27 Normal horse serum Cat# MP-7402 kit

Inc. (min): 10:00

emperaUire: Ambient Dispense type: ! 50 rC

Step type: Reagent

Step Reagent Supplie

28 TBS-t

Step type: Reagent Inc. (min): 30:00 t emperature: Ambient Dispense type: ! 5 p.L

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

29 *BondWashSolution

30 *BondWashSolution

31 *B o nd WashSoi u t ion

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

32 ^'« Bond Was h S ol ut i on

Step Reagent Supplier: Vector Lab

Cat# MP-7402 kit

33 Horse anti-mouse

IgG

Inc (min): 20:00 emperalure: Ambient Dispense type: 150 pL

Step type: Reagent

Step Reagent Su pp ii er: Le ica Mi emsystems

Cat# AR9590

34 ^« Bon ashSoiution

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

35 * BondWashSolution

Step type: Wash ine. (min): 2:00 femperature : Am Pi eni Dispense type: 150 pL

Step Reagent Supplier:

36 ^« Bond W as. h S ol ut i on

Step type: Wash Inc. (nun): 2:00 emperature: Ambient Dispense type: !SO pL

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

37 ^BondWashSolution

38 «Peroxide Block

Step type: Reagent Inc. (min): 8:00 tempera in ft" Ambi e n i Dispense type: 150 mϊ-

Step Reagent Su pp ii er: Le ica Mi cm systems

Cat# AR9590

39 ^« BondWashSolution

Step type: Wash Ine. (min i: 0:00 PemperaUive. Ambien Dispense type: 150 mϊ.

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

40 * Bond W ashSohuion

Step type: Wash Inc. (min): 0:00 p ramrc: Ambient Dispense type: Open

Step Reagent Supplier: B. BRA UN Medical Inc. #R50QQ-01

42 * Deionized W ter

Step type: Rea gem Inc. (min): 0:00 emperatnre : A mbient Dispense type- i 'iO L

Step Reagent Supplier: B. BRAUN Medi

43 *Ddcmlzed Water

Step type: Wash bsc. (min): 0:00 ernperalme: Ambient Dispense type. 150 pi.

Step Reagent Supplier: Bond Polymer Refine Detection kit

44 ^Mixed DABRefine Cal# DS9 00

Step type: Reagent Inc. άt··h >: 2:00

f ernperature : Are bi en Dispense type: 150 pL

Step Reagent Supplier: Bon Polymer Refine Detection kh

45 Mixed DAB Refine Cat# DS9800

Step type: Reagent Inc. (min >: 5:00

ariperatme: Am ie Dispense type: 150 pL

Step Reagent Supplier: B. BRA UN Medical

46 ' Deionized Water

Step type: Wash Inc. (min): 0:00 emperalnre : A mbient Dispense type- i 'iO L

Step Reagent Supplier: B. BRAUN Medical Inc. #R5000-OI

47 ^Deionized Water

Step lypc: Wash 5nc. (min): 0.00 ernperalme: Ambient Dispense type. 150 pi.

48 "’Deionized Water

Step type: Wash Inc. (min): 0:00 Temperature: Ambient Dispense type: ISO pi

Step Reagent Supplier: Bo d Polymer Refi

49 *Heniatoxvhn

Step type: Reagent Ine (min) i: i0:00

Step Reagent Supplier: 8. BRAUN Medical Inc. 8R5000-01

50 "’Deionized Water

Step type: Wash inc. (min): 0:00 Temperature: Amibient Dispense type. Ϊ50 pi.

Step Reagent Supplier: Leica Microsystems

Cat# AR9590

51 ^' «Bond Was h S ol ut i on

Step type: Wash inc. imm ): 1 :00 Temperature: Ambient Dispense type: ! 50 pL

Step Reagent Supplier

52 " BondWashSolution

Step iype: Wash Inc. (min): 0:00 Temperature: Ambient Dispense type : 150 pL

Step Reagent Supplier: 8. BRAUN Medic, .d

53 "Deionized Water

Step type: Wash inc. (min): 0:00 Temperature: Ambient Dispense type: 150 pi.

EQUIVALENTS AND SCOPE

[00156] In the claims articles such as“a,”“an,” and“the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include“or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

[00157] Furthermore, the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and'or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and'or features. For purposes of simplicity, those embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms“comprising” and“containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any claim, for any reason, whether or not related to the existence of prior art.

[00158] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.